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Lay Abstract  
 
 
Since tumours were first viewed on the predecessors of modern 
microscopes in the late 1860s, scientists observed notable visual differences 
from healthy tissues. Most of these differences were in the nucleus of the cell, 
which is easy to see through the microscope due to its size and darker staining 
because this is where the genome is kept. Most nuclear changes were in size 
and shape and these changes are still used today for both diagnosis and grading 
of tumours because nuclear size changes become stronger in later stage higher 
grade tumours that are more aggressive. This thesis investigates which proteins 
at the nuclear surface could be the factors leading to these changes in nuclear 
size and tries to dissect if the nuclear size change are a side effect of 
tumourigenesis or are a driving feature making the tumour that if targeted might 
improve patient survival. One of the biggest problems faced by researchers is 
that these nuclear modifications are specific for each type of cancer. Most cancer 
research is focused on finding common factors involved in cancer progression, 
but this work starts with the hypothesis that it may be better to target these tissue-
specific differences. It has been established in our lab that proteins resident at 
the membrane defining the nucleus, the nuclear envelope, are tissue-restricted, 
therefore each type of tissue and accdordingly each tumour derived from that 
tissue has a different subset of these Nuclear Envelope Transmembrane proteins 
(NETs). As these NETs are tissue specific and alteration of nuclear size and 
shape are different for each tumour tissue type, we postulate that they might 
contribute to altering nuclear size. Therefore, their loss or gain during cancer 
progression may explain the differences identified in each tumour type. Indeed, 
we found several such NETs influence nuclear size and are altered in different 
tumour types. Targeting these proteins with drugs on top of existing 
chemotherapy regimens might improve patient survival. We also thus searched 
for drugs that alter nuclear size, expecting that they might be able to restore 
correct nuclear size in tumours. We searched for drugs affecting three different 
tumour types where nuclear size changes are linked to lower survival rates: 
prostate cancer, colon cancer, and lung cancer. We identified some drugs 
affecting nuclear size for each of the different types of cancer; however, 
interestingly, each cancer type had a unique set of drugs affecting nuclear size. 
These findings suggest it may improve patient survival if some of these drugs are 
added to chemotherapy regimens and by specifically targeting the tissue 
containing the cancer this might also reduce organismal toxicity, a side-effect of 
chemotherapy that greatly lowers quality of life for the patients. Further applying 
this principle to other cancers tissue types and testing for better drugs targeting 









Nuclear size normally scales with cell size and is maintained throughout 
the cell cycle, but in cancer this karyoplasmic ratio, the ratio between the 
cytoplasm and the nucleoplasm, is disrupted, particularly in certain types of more 
metastatic tumours from certain cancer types.  As the direction and scale of 
nuclear size changes differs for particular tumour types — for example in breast 
cancer larger nuclear size correlates with increased metastasis while for lung 
cancer smaller nuclear size correlates with increased metastasis — there must 
be tissue-specific drivers of these changes. This study aimed to screen several 
tissue-specific nuclear envelope transmembrane proteins (NETs) and separately 
a small molecule compound library for effects on nuclear size in cell lines from 
different cancer types. The NET screen was engaged in cells from prostate 
cancer (PC3) and cervical carcinoma (HeLa) and different sets of NETs affected 
nuclear size in each tumour type. Interestingly, these NETs also exhibited altered 
gene copy numbers in patient samples from particular tissue cancer types where 
their effects on nuclear size correlated with the directionality of nuclear size 
changes in the tumours. The compound screen was performed on the PC3 cells 
and on colonic adenocarcinoma (HCT116) and small cell lung carcinoma (H1299) 
cells. Each cancer type screened was affected by different compounds, so that 
both screens suggest a tissue-specific regulation of nuclear size. Interestingly, 
these compounds also reduced cell migration in wound healing assays, 
suggesting they might reduce tumour metastatic spread. Finally, merging both 
screens, the NET DHRS7/NET50 and the compound estradiol proprionate that 
both affect nuclear size in the prostate cancer model seem to intersect in the 
same pathway and we anticipate that further study will elucidate a mechanism for 
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1. Introduction  
	
1.1 Nuclear size regulation in cancer  
	
Phenotypic and morphological alterations in cell nuclei during cancer 
progression were first discovered in the mid-1800s when the first microscopes 
capable of resolving structures down to 1 µm resolution were built. One of the 
earliest descriptions of these changes, published in 1860 by Lionel S. Beale 
(King’s College London), reported alteration of nuclear size and shape in the 
sputum of a patient with cancer of the pharynx (Beale 1860). These 
morphological alterations of the nuclear structure and size have been used for 
diagnosis of cancer ever since. Eighty years after Beale's seminal work, 
George Papanicolaou developed a stain to visualize cytoplasmic and nuclear 
structural features for an accurate diagnosis/staging of cervical cancer, setting 
a standard tool still used today (Cibas and Ducatman 2014). Though 
subsequent advances added many other altered nuclear features to fine-tune 
diagnoses such as chromatin organization and numbers and sizes of nucleoli, 
the nuclear size and shape changes are the most evident characteristics that 
can be distinguished by light microscopy in tumour progression and are highly 
characteristic for a given tumour type. At least a dozen different tumour types 
exhibit changes in nuclear size independent of ploidy that correlate with a 
worse prognosis for the patients (Cibas and Ducatman 2014; de Las Heras et 
al. 2014) (Table 1); hence, size and shape are used prognostically for stage 
and progression of each different tumour type (Zink, Fischer, and Nickerson 
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2004). Determining the function and mechanisms underlying these nuclear 
size changes in cancer is complicated as they tend to be tissue-specific in 
degree and direction, with some cancers showing smaller nuclei correlating 
with increased metastatic potential like osteosarcoma and lung carcinoma (de 
Andrea et al. 2011; Ladekarl et al. 1995) while others present larger nuclei that 
correlate with increased metastatic potential as in breast and prostate cancers 
(Abdalla et al. 2012; Nandakumar et al. 2012; Rashid and Ul Haque 2011; Tan 
et al. 2001). 
  The karyoplasmic ratio, the ratio between the nucleoplasm and the 
cytoplasm volume, is maintained during the cell cycle (Cavalier-Smith 2005; 
Edens et al. 2013) throughout which the nucleus typically increases several-
fold in volume. Moreover, a general mechanism for this size scaling is 
conserved from higher eukaryotes to yeast (Jorgensen et al. 2007; Neumann 
and Nurse 2007). However, this karyoplasmic ratio scaling is not maintained 
in more metastatic cancer cells. This raises the question of whether the scaling 
disruption is just an indirect side effect of other changes that drive the tumour 
or if the nuclear size change itself contributes an advantage to or even 
underlies tumour generation. With the many functions now known for the 
nuclear envelope (NE), advantages could range from changes in gene 
regulation/signaling to mechanical nuclear aspects enabling faster migration 












Cancer type Nuclear Size 
change 
Reference 
Breast cancer + (Abdalla et al. 2012; 
Nandakumar et al. 
2012; Tan et al. 2001) 
Male Breast cancer  + (Veta et al. 2012) 
Cervical cancer + (Saad et al. 2006; 
Slater et al. 2005) 
Small-cell Cervical cancer + (Giorgadze et al. 2012) 
Colorectal cancer + (Eynard et al. 2009) 
Epidermal squamous cancer + (Malhotra et al. 2013) 
Cutaneous soft tissue sarcoma  + (Meachem et al. 2012) 
Gastric carcinoma + (Ikeguchi et al. 1999) 
Lung squamous cell carcinoma - (Ladekarl et al. 1995) 
Liver cancer  + (Yan et al. 2012) 
Melanoma + (Mossbacher et al. 
1996; Na et al. 2009) 
Invasive meningioma + (Madsen and Schrøder 
1996) 
Oral squamous carcinoma + (Natarajan et al. 2010) 
Osteosarcoma - (de Andrea et al. 2011) 
Ovarian cancer + (Zeimet et al. 2011) 
Pancreatic cancer  + (Taira et al. 2012a) 
Prostate adenocarcinoma  + (Rashid and Ul Haque 
2011) 
Papillary thyroid carcinoma + (Shih et al. 2013) 
Urinary bladder carcinoma + (Fukuzawa et al. 1995; 
Helander, Hofer, and 
Holmberg 1984; van 
Velthoven et al. 1995) 
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1.2 Nuclear envelope changes in cancer  
	
The NE undergoes extreme alterations and disruptions during cancer 
progression generally, but the changes are often tissue specific, with the 
particular phenotype depending on the tissue in which the cancer starts its 
development. For each tissue cancer type there are characteristic changes in 
size and morphology that moreover correlate with stage and grade of that 
cancer and so are used both diagnostically and prognostically (Fig 1A). As the 
NE forms the "walls" of the nucleus, nuclear size changes require growth at 
the NE and shape changes likewise involve deformation of the NE. Thus, it is 
reasonable to postulate that the physically observed changes under the 
microscope are driven at least in part by changes in proteins at the NE. The 
NE is not just the primary barrier between cytoplasm and the genetic material, 
but recent studies show that it has important signalling functions, contributes 
to cell migration through its cytoskeletal connections at the ONM, and through 
its many connections to chromatin at the INM adds additional layers of gene 
regulation as well as contributing to DNA-damage repair. Accordingly, more 
interest is being raised to understand the role of this compartment in the 
development of cancer and the possibility that the NE changes may contribute 
to as well as reflect disease progression.  
A general categorization for nuclear envelope changes undergone in cancer 
progression has been proposed by Fisher that breaks down these alterations 
into three main general groups: 
- NE changes associated with chromosomal instability 
- Conserved NE structural features within a genetically 
unstable population 
- NE changes in the absence of chromosomal instability 
The first group is the most common phenotype identified in solid tumours as 
around 90% of them present chromosomal instability (Holland and Cleveland 
2012). Chromosomal instability phenotypes across cancers are quite 
heterogeneous and can yield a variety of different morphological changes even 
within the same tumour mass such as alteration of the nuclear size and shape, 
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with the presence of polylobulation and deep infoldings. In addition to these 
alterations, this type of cancer is characterised by the presence of micronuclei, 
a characteristic phenotype of chromosomal instability formed when mis-
segregated chromosomes acquire an independent NE from the nucleus 
containing the bulk of the chromosomes (Fig 1B) (Holland and Cleveland 
2012). Nuclei of this group when in interphase can be visualized by a different 
cell-to-cell hematoxylin staining, due to a different DNA content resulting from 
the failure to equally distribute the genetic material to the daughter cells. For 
these types of cancer the shape of the NE is altered in aneuploid cells, but this 
change is maintained through cancer progression and therefore does not 
provide a basis for grading later stages of the cancer. As these cells lose the 
ability to retain a spherical or ovoid nuclear shape, they offer a simple typical 
phenotype that can be used by cytopathologists as a distinctive mark for the 
original cancer diagnosis (Samanta and Dey 2012).    
The second group, in which NE features are conserved in the presence 
of chromosome instability, shows an increased nuclear lamina surface area or 
nuclear volume compared to cytoplasmic volume (N/C ratio). Moreover, these 
cancers show fragile nuclear lamina, a typical trait in the “small-cell 
carcinomas” (Fig 1C). This type of tumour can arise from anywhere in the body 
and is highly genetically unstable (Wistuba, Gazdar, and Minna 2001). Despite 
the elevated chromosomal instability of this type of cancer it conserves a series 
of morphological alterations, with the NE lacking strength and nuclei molding, 
assuming the shape of nearby nuclei or objects (Fischer 2014). 
 Finally, cells included in the third group, where NE changes occur in the 
absence of chromosomal instability, present long longitudinal intranuclear 
cytoplasmic inclusions and a nuclear groove. These alterations are commonly 
found in papillary thyroid carcinoma, Langherhans cell histiocytosis and adult 
granulosa cell tumours, for which they are precise diagnostic features (Fig 1 
D-E)(Fischer 2014). This group will be the focus of this thesis work because 
the changes are very characteristic for each tumour/tissue type and occur with 
the change to more severe grading for later cancer stages with increased 
metastasis.  Of particulate note, because changes in ploidy do not occur in this 
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group the changes in nuclear size and morphology are more likely to involve 







same	 manner	 as	 normal	 thyroid	 epithelium.	 Diagnostic	 features	 for	 the	 first	 group	 include	 the	 long	 linear	
infoldings	 of	 the	NE	 (short	 thin	 arrows).	 Also	 very	 important	 diagnostically	 are	 the	 spherical	 invaginations	 of	




needle	 aspirations	 of	 normal	 pancreatic	 ductal	 cells	 (left),	 and	 the	 earliest	 known	 stage	 of	 a	 pancreatic	
adenocarcinoma	 (right).	Note	 the	 typical	 characteristics	 of	 this	 group,	 the	 intranuclear	 cytoplasmic	 inclusions	
(long	 thick	 arrows)	 and	 nuclear	 grooves	 (short	 thin	 arrows).	 E.	 Fine-needle	 aspiration	 samples	 showing	 a	
comparison	 of	 normal	 ductal	 cells	 (left)	 with	 a	 “high-grade,”	 chromosomally	 unstable,	 and	 aneuploid	 ductal	




1.3 Nuclear structure and organization  
	
The NE is comprised of outer (ONM) and inner (INM) nuclear 
membranes and associated proteins (Fig 2) (Callan, Randall, and Tomlin 
1949; Prunuske and Ullman 2006). The membranes are separated by a lumen 
and connected where nuclear pore complexes (NPCs), comprised of ~30 core 
proteins, are inserted (Grossman, Medalia, and Zwerger 2012; 
Suntharalingam and Wente 2003). NPCs contain multiple copies of only three 
transmembrane proteins, but there are hundreds of other Nuclear Envelope 
Transmembrane proteins (NETs) in both membranes (Korfali et al. 2010, 2012; 
Schirmer et al. 2003; Wilkie et al. 2011). Functions of ONM NETs are just 
beginning to be discovered, but many connect to cytoplasmic filaments (Buch 
et al. 2009; Crisp et al. 2006; Pfisterer, Jayo, and Parsons 2017; Wilhelmsen 
et al. 2005; Wilkie et al. 2011) while others function in cell cycle regulation 
(Johnson et al. 2004; Korfali et al. 2011; Srsen, Korfali, and Schirmer 2011). 
Thus far, many INM NETs characterized make connections important for 
genome organization, gene regulation, and signalling (Czapiewski, Robson, 
and Schirmer 2016; Holaska, Rais-Bahrami, and Wilson 2006; Kim et al. 2004; 
De Las Heras et al. 2017; Markiewicz et al. 2006; Parada, McQueen, and 
Misteli 2004; Robson et al. 2016, 2017). INM NETs also connect to a polymer 
of the type V intermediate filament nuclear lamins that confers structural 
stability to the nucleus (Crisp et al. 2006; Meinke and Schirmer 2015; Prunuske 
and Ullman 2006). These proteins such as Emerin, LAP1, LAP2b, LBR and 
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MAN1 not only have the ability to interact with lamins in different ways but are 
also able to recruit chromatin binding proteins such as HP1 and BAF, 
conferring them a central role in maintaining regions of the genome in a 
repressed state at the periphery of the nucleus (Solovei et al. 2013). 
The NE is also connected to the cytoskeleton (Fig 2), helping the 
nucleus to maintain its position, shape and size and to transduce signalling 
stimuli deriving from the cytoplasm and the plasma membrane. The primary 
proteins involved in this connection are SUN-domain containing proteins of the 
INM and KASH-domain containing proteins, known as Nesprins, of the ONM. 
Together these form the Linker of Nucleoskeleton and Cytoskeleton (LINC) 
complex (Crisp et al. 2006) that also supports mechanosignal transduction to 
the nucleus (Ho et al. 2013; Swift et al. 2013). The LINC complex has been 
linked to nuclear size regulation and could contribute to cancer progression 
through the ability of controlling nuclear positioning and influencing migration 
(Gant Luxton et al. 2011; Lu et al. 2012; Luxton et al. 2010).  
On the inner side the NE is in connection with the nuclear lamina, that 
offer support for the mechanical stability of the nucleus (Broers et al. 2004; 
Lammerding et al. 2004b; Lee et al. 2007) and therefore could be a major 
factor that can influence the nuclear size. When cells migrate and invasion 
cells have to navigate through tight spaces in the extracellular matrix and cell 
enjoinments that are smaller than the nucleus, this can happen through 
deformation of the nucleus (McGregor, Hsia, and Lammerding 2016) and 
remodeling of the nuclear stiffness manly dependent of altering the expression 
of the level of lamin A levels (Lammerding et al. 2004a, 2006). This results in 
cell lacking lamin A/C or with reduced expression levels to migrate faster on 
narrow constrictions (Davidson et al. 2014; Harada et al. 2014), suggesting 
that lamins could explain the alteration of nuclear size normally detected during 
cancer progression.   
During mitosis of higher eukaryotes the NE disassembles to allow the 
sister chromatids to be separated and the reassembled daughter nuclei are 
much smaller compared to the mother cell. This is because at the end of S-
phase the genome has doubled to 4N, the chromatin is decondensed and the 
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nucleus is filled with proteins and RNA whereas the reforming NE surrounds a 
2N genome that is highly condensed. In general the nuclear volume increases 




with	the	ER	and	 is	 formed	by	an	 inner	and	outer	nuclear	membrane	separated	by	a	 lumen,	 interrupted	by	the	
nuclear	pore	complex.	Different	proteins	insert	in	both	the	outer	and	inner	nuclear	envelope	membranes	called	




1.4 Karyoplasmic ratio and factors that can regulate nuclear size 
	
The ratio between the nucleoplasmic and the cytoplasmic volume, 
known as the karyoplasmic ratio or volume, has been proposed as one of the 
key mechanisms for a signalling feedback loop for scaling organelles, and to 
potentially trigger important checkpoints during the cell cycle (Cavalier-Smith 
1978). The karyoplasmic ratio has been shown to be constant throughout the 
cell cycle and this feature is highly conserved in most unicellular and 
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multicellular organisms (Cavalier-Smith 2005), suggesting a key role for 
nuclear volume in determining cell size and vice versa. The mechanisms by 
which this process of scaling are regulated are still elusive and pose a 
challenge to researchers trying to elucidate the key players in how cells scale 
up or down the karyoplasmic ratio. One of the most accredited theories is that 
cytoplasmic volume and the amount of available NE components directly limit 
nuclear size (Fig 3). This is supported from experiments of heterokaryon 
formation between hen erythrocytes with HeLa cells, leading to expansion of 
the nucleus with changes in chromatin organization (Harris 1967).  
Although how the karyoplasmic is maintained is still wildly debated, 
what has been clear for the last half century is that this ratio is altered in cancer 
cells (Cibas and Ducatman 2014; Frost 1986). This allowed the setup of 
standards to determine the presence and progression of cancer in standard 
haematoxylin and eosin stained biopsies. The nucleus and the nuclear 
envelope are two highly organized and specialized compartments of the cell, 
and dozens of different factors can influence directly or indirectly the 
maintenance of a normal nuclear size that will be explained in the following 




alter	 nuclear	 size	 altering	 the	 karyoplasmic	 ratio,	 one	 of	 the	 morphological	 hellmarks	 of	 cancer.	 	 Enzymatic	
functions	of	NETs,	for	example	lipid	synthesis	enzymes,	lipid	flippases	or	sterol-modifying	enzymes,	can	directly	






1.5 Components of the Nuclear Envelope that can regulate nuclear 
size  
	
	 As is becoming more and more clear thanks to extensive research in 
the nucleus field, the NE is not just a mere barrier that separates the genetic 
information from the components of the cytoplasm, but is a dynamic organelle 
participating actively in different cell regulation processes. The NE comprises 
of several proteins with different functions that can also be responsible for 
regulation or maintenance of a correct nuclear size, and for which alteration 
during cancer progression may give cancer cells advantages resulting in more 
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aggressive tumours. Although there are several functional overlaps for 
proteins at the NE, as for example mechano-transduction of stimuli from the 
cytoplasm to the nucleoplasm, in general the INM has the functions to interact 
with chromatin and generate a transcriptionally repressed environment though 
it is more a regulatory environment than repressive as in cell types with less 
peripheral heterochromatin the NE can promote gene expression. This side of 
the NE comprises of the intermediate filament meshwork generated by lamins, 
proteins that interact with lamins and chromatin such as Emerin, LAP2 or 
MAN1 and the SUN proteins part of the LINC complex. On the other hand, the 
ONM has roles of connecting with the cytoskeleton, nuclear positioning and 
regulation of nucleoplasmic-cytoplasmic transport. This side of the NE 
comprises of Nesprin proteins that, connecting with the SUN proteins in the 
INM, form the cytoplasmic side of the LINC complex. Aside from these well-
known proteins, there are other NETs that can localize either in the INM or the 
ONM and can interact with soluble factors and associated proteins, some of 
which may actively regulate nuclear size.  
	
 
1.5.1 Lamins  
 
Lamins are good candidates to limit/regulate nuclear size as they form 
an intermediate filament polymer, the nuclear lamina, that provides the main 
mechanical stability and architecture to the nucleus (Broers et al. 2004; 
Lammerding et al. 2004b; Lee et al. 2007). Moreover, lamins are also the most 
abundant NE proteins at ~9 million copies per mammalian cell nucleus (Busse 
et al. 2011). Thus their limitation due to down regulation or degradation might 
be predicted to restrict nuclear growth. Consistent with this view, lamins 
influence nuclear size in Xenopus laevis embryos in a manner that depends 
on import of lamin B3 which is reported to be required for NE growth during 
egg development (Jevtic and Levy 2015). Both Xenopus and mammalian 
studies have concluded that lamins are essential for nuclear scaling during 
interphase and their limitation leads to failure in proper nuclear scaling 
(Jenkins et al. 1993; Jevtić et al. 2015; Newport, Wilson, and Dunphy 1990). 
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Notably, from the standpoint of a limiting function, several NPC proteins have 
also been linked to cancer and nuclear size regulation (Simon and Rout 2014). 
Lamins could also contribute to nuclear shape changes in cancer cells as their 
loss or mutation in several heritable diseases yields defects in nuclear 
morphology (Brown et al. 2008; Schirmer, Guan, and Gerace 2001; Sullivan 
et al. 1999). 
 Despite these results, it is unlikely that, apart from being limiting for 
growth, lamins could actively regulate nuclear size on their own as both the 
total amount of lamin protein and the relative amounts of different lamin 
subtypes in the nuclear lamina change during development (Lehner et al. 
1987; Röber, Weber, and Osborn 1989; Stick and Hausen 1985). A-type 
lamins, encoded by the LMNA gene, are present in the earliest embryonic 
stages from maternal protein, but are not expressed at these stages so that 
they quickly disappear and are not present through most embryonic stages 
until they are expressed and reappear later in tissue differentiation 
(Benavente, Krohne, and Franke 1985; Broers et al. 1997).  
 The changes in lamina constitution in development is interesting in light 
of changes observed in lamina constitution in some cancer types. The general 
tendency observed is that B-type lamins continue to be expressed in tumours 
while A-type lamins are down-regulated (Agrelo et al. 2005; Kaufmann et al. 
1991; Venables et al. 2001). Because A-type lamins appear later in 
development, this led to the idea that their loss reflects retro-differentiation or 
de-differentiation and so might drive or at least reflect the return to a more 
proliferative and undifferentiated state (Kuzmina et al. 1984). However, 
research in this direction was dropped when it was observed that for some 
cancer types such as colorectal cancer the more metastatic tumours had 
increased A-type lamin levels (Willis et al. 2008). Though at the time this 
appeared to kill the retro-/de-differentiation theory, subsequent independent 
work outside the cancer field found that in epithelia such as the colonic crypts, 
the early progenitor cell lineages at the base of the crypts that are the most 
proliferative in fact express lamin A. Expression of lamin A then disappears 
along the sides of the crypt as the cells differentiate and it becomes expressed 
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again in the more differentiated cells at the top of the crypts (Willis et al. 2008). 
Much more recent work additionally revealed that lamin A functions inside the 
nucleus can influence the expression of genes encoding proteins that 
contribute to actin bundling and dynamics such as T-plastin (Willis et al. 2008). 
This could explain how a lamin A-expressing tumour could lead to metastasis 
and tumour spread as cell mobility would be increased and, indeed, other 
studies with lamin A knockout cells found that in the absence of lamin A, cells 
migrated into a scratch wound more slowly (Ho et al. 2013; Lee et al. 2007). 
Interestingly, while this beautifully explains how lamin A-expressing tumours 
can be more metastatic, it leaves us even more in the dark with regard to 
understanding the contribution of loss of lamin A in most cancer types to 
tumorigenesis. Moreover, as lamins are widely expressed in all the tissues, 
this is not consistent with the nuclear size tissue specificity shown in different 
types of cancer, suggesting the involvement of more tissue specific proteins 
contributing to specific cancer phenotypes.  
 
1.5.2 Nuclear pore complex (NPC) 
	
 Another key perinuclear structure that can affect nuclear size and shape 
by mechanical support or by its function is the NPC. As the NPC in vertebrates 
is a >60 MDa macromolecular structure that facilitates nuclear-cytoplasmic 
transport and interacts with different NETs it is easy to speculate an important 
role for this structure in the regulation of nuclear size and shape. Nuclear size 
could be influenced by the amount of transported constituents into the 
nucleoplasm, and in fact defective assembly of NCPs in mammalian cells 
results in a reduction in nuclear growth (Franz et al. 2007; Walther et al. 2003). 
At the same time an increase in the number of NPCs is unlikely to account for 
nuclear growth, as shown when inhibition of de novo synthesis did not 
influence the nuclear growth rate (Maeshima et al. 2010). This could be due to 
the high capacity of transport of this structure, and there may be a threshold 
level and it does not take many NPCs to achieve that threshold. Therefore, the 
number of NPCs would need to be extremely altered to sufficiently block the 
transport of molecules into the nucleus. As most of proteic components of the 
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nucleoplasm are synthetized in the cytoplasm and rely on the association with 
their nuclear transport receptors and interaction with nucleoporins to be 
translocated, the NPC can be considered an indirect regulator of nuclear size, 
which if defective could limit the amount of molecules or proteins necessary 
for the maintenance of normal nuclear size and shape such as lamins. In fact, 
alterations of nuclear transport are frequently detected in cancer cells (Kau, 
Way, and Silver 2004), but they influence a vast range of mechanisms, such 
as alteration of expression levels, transport of tumour suppressor proteins, or 
posttranslational modifications of the nuclear transport receptor and their 
partner proteins.  
Moreover, other than limiting the resources necessary for nuclear 
growth, cytoplasmic to nucleoplasmic transport can influence the nuclear size 
with the import of specific factors resident in the cytoplasm. This has been 
demonstrated in X. laevis and X. tropicalis where modulating the levels of 
importin a and Ntf2 was sufficient to alter nuclear size in both of the egg 
extracts, with importin a positively modulating bulk import rates and Ntf2 
negatively regulating nuclear size by slowing down large cargo translocation 
through the NPC (Riddick and Macara 2005). Alteration of the transport of 
different factors is commonly seen in different cancers, Moreover importin a 
expression has been suggested as a good biomarker for aggressive cancers, 
as it is upregulated in metastatic breast (Dahl et al. 2006; Gluz et al. 2008) and 
non-small-cell lung cancer (Wang et al. 2011). 
 
1.5.3 Linkers of the nucleoskeleton to the cytoskeleton (LINC) complex  
 
Connections between the nucleus and the cytoskeleton contribute to 
both the overall mechanical stability of the cell and its migratory capacity 
(Broers et al. 2004; Lammerding et al. 2004b; Lee et al. 2007). Such 
connections could in theory enable all major cytoplasmic filament systems to 
contribute to nuclear size regulation as actin microfilaments, microtubules and 
intermediate filaments all connect to the NE (Roux et al. 2009; Wilhelmsen et 
al. 2005; Wilkie et al. 2011). As for lamins, nesprins also contribute to nuclear 
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size, so that mutations in nesprins have been linked to muscular dystrophies 
that also exhibit aberrant NE organization (Zhang et al. 2007) and two nesprins 
in particular, Nesprin-2 and Nesprin-3, have been proposed to form a 
cytoplasmic cage around the nucleus to contribute to its mechanical support 
(Lu et al. 2012). Moreover, NE blebbing and severely misshapen nuclei are 
the result of silencing the Nesprin-2 giant protein (Luke et al. 2008a), and 
removal of the nesprin proteins from the NE leads to an expansion of the NE 
lumen (Zhang et al. 2007).  
The LINC complex is also involved in nuclear positioning and recent 
studies have shown the involvement of Transmembrane Actin-associated 
Nuclear (TAN) lines, composed of nesprin-2G and SUN2, in centrosome 
orientation (Gant Luxton et al. 2011; Luxton et al. 2010). As centrosome 
orientation has been directly implicated with cell migration (Gomes, Jani, and 
Gundersen 2005; Schmoranzer et al. 2009) it is easy to speculate that aberrant 
expression of these proteins in tumours can result in advantages in the 
migratory potential for cancer cells. Moreover, as these proteins link the 
nucleus with a complex meshwork of microtubules, actin and intermediate 
filaments, alteration of the amount of proteins can directly result in alteration 
of the nuclear size due to gain or loss of anchor points with the cytoplasmic 
connections. Furthermore, regarding the possible importance of the LINC 
complex in nuclear size regulation, it has been shown that siRNA knockdown 
of Nesprin-1a leads to enlarged cell size (Luke et al. 2008a), unbalancing the 
karyoplasmic ratio, and knockout mice for the giant isoform of Nesprin-2 
present a thicker dermis attributed to enlarged nuclear size (Zhang et al. 2007). 
   
 
1.5.4 Inner nuclear membrane NETs  
 
In the same way that SUN and Nesprin family proteins segregate 
between the ONM and INM, so do other NETs. There are now many hundreds 
of NETs that have been identified by proteomics of isolated nuclear envelopes, 
most of which are tissue-restricted in expression or NE targeting (Fig 4) (Korfali 
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et al. 2010, 2012; Robson et al. 2016; Wilkie et al. 2011), suggesting that they 
might contribute to the tumour tissue-type specificity of nuclear size effects in 
cancer. Over 50 NETs have been characterized by super resolution 
microscopy for their accumulation in the ONM or INM, with a strong majority 
favouring the INM (Korfali et al. 2010; Malik, Korfali, et al. 2010; Wilkie et al. 
2011).  
 Many INM NETs interact with lamins and chromatin and play important 
roles in gene/chromosome positioning, chromatin organization and 
epigenetics, and genome regulation (Mattout-Drubezki and Gruenbaum 2003; 
Robson et al. 2016; Schirmer and Foisner 2007; Solovei et al. 2013; Srsen et 
al. 2011). Though most of the general radial chromosome positioning is based 
on gene density (Croft et al. 1999), each tissue also has a subset of genes and 
chromosomes that reposition during differentiation in a tissue-specific manner 
(Kim et al. 2004; Morey et al. 2008; Parada et al. 2004; Szczerbal, Foster, and 
Bridger 2009). The general positioning trends appear to be driven by 
heterochromatin interactions with lamins and the NET, lamin B receptor (LBR), 
that binds directly to heterochromatin protein 1 (HP1) (Solovei et al. 2013). In 
general, the periphery tends to be a more silencing environment based on 
expression profiles and epigenetic marks of genome-wide identified genes that 
reside there (Akhtar et al. 2013). The more tissue-specific gene and 
chromosome positioning patterns are directed by tissue-specific NETs. For 
example, liver NETs NET45/Dak and NET47/TM7SF2 are important for 
positioning to the NE of chromosome 5 in liver cells (Zuleger et al. 2013) and 
muscle NETs NET39/PPAPDC3, Tmem38A, and WFS1 are important for 
positioning to the NE of several genes that need to be tightly shut down in a 
temporal fashion later in muscle differentiation though they are needed in 
earlier stages (Robson et al. 2016). Interestingly, there are also many genes 
involved in cell proliferation that reposition to the more repressive environment 
of the NE in tissue differentiation because they must be tightly shut down when 
the cells exit the cell cycle to differentiate (De Las Heras et al. 2017; Robson 
et al. 2016, 2017). Thus, alteration of the normal expression patterns for such 
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NETs in cancer could support metastasis by increasing expression of 
proliferative genes.  
 Other important proteins at the INM that may contribute to nuclear size 
regulation through contacts with the chromatin are LAP2, Emerin and MAN1. 
These proteins share the so called LEM domain, a bi-helical structural domain 
that can interact with several chromatin binding proteins (Cai et al. 2001). An 
important interaction, for both LAP2 and Emerin, is the Barrier-to-
Autointeration Factor (BAF) involved in binding chromatin and repressing it at 
the NE (Cai et al. 2007; Shumaker et al. 2001). Moreover, both NETs are able 
to directly bind the histone deacetylase HDAC3 to further silence chromatin 
(Demmerle, Koch, and Holaska 2012) allowing promotion of chromatin 
compaction at the NE. It is clear that loss of these proteins during cancer 
progression can influence nuclear size regulation, both through loss of 
connections between the NE and chromatin and by release and activation of 








1.5.5 Outer nuclear membrane NETs 
 
Some ONM NETs, like nesprins, mediate interactions with cytoplasmic 
filaments. For example, NET5/Samp1 is important for associations between 
the nucleus and the centrosome that organizes microtubules (Buch et al. 
2009). Others are involved in cell cycle regulation, for example NET4/Tmem53 
activates a seemingly stress-induced p38 kinase pathway that results in cell 
cycle withdrawal when its levels are perturbed (Korfali et al. 2011). Another 
ONM NET affecting the cell cycle, NET31/Tmem209, is able to alter cancer 
cell growth when overexpressed in lung cancer cells and interestingly is 
upregulated in lung cancer cells and normal testis that contain highly 
proliferative cells (Fujitomo et al. 2012). As loss of proliferation control is a 
hallmark of cancer cells, these NETs could also be highly relevant to 
metastatic tumours, though they have thus far not been linked to nuclear size 




 Due to the close interactions between the nucleus, NETs, LINC complex 
and the cytoskeleton, alterations of the main filament network of the cell can 
influence and alter the nuclear morphology. Throughout cell movement, the 
nucleus undergo shape and size alteration with the cytoskeleton rearranging 
actin filaments and microtubules to allow the process of migration. The nucleus 
is positioned away from the leading edge creating a leading 
edge/centrosome/nucleus axis in the direction of the migration. This nuclear 
rearward movement is driven by an actin retrograde flow mediated by myosin 
and Cdc42 (Barnhart et al. 2010; Gomes et al. 2005; Tsai and Gleeson 2005). 
The nucleus is also drastically pushed, pulled and deformed during migration 
through the ECM and endothelial cells possible by the activation of the 
ESRCT-III machinery and formation of perinuclear actin network that protect 
the nucleus while transitioning through confined spaces (Denais et al. 2016; 
Raab et al. 2016). It results clear that alterations of the expression or inhibition 
of the assembly of the cytoskeletal elements could result in the severe 
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alteration of the nuclear size and shape. This has been elegantly demonstrated 
with inhibition of the cytoskeletal filaments assembly preventing alteration of 
the nuclear shape and position when the cell is mechanically stressed with a 
micropipette (Ghosh et al. 2008; Maniotis, Chen, and Ingber 1997).    
  
 
1.5.7 Non-resident factors  
 
Different cytoplasmic factors have been shown to influence nuclear 
scaling. As the karyoplasmic ratio has been established to be maintained 
throughout the cell cycle, one of the first factors that has been investigated for 
the ability to alter nuclear size is the cytoplasmic volume. To test the 
dependency of nuclear size on the cytoplasmic volume a study generated a 
cytokine S.pombe mutant, allowing the formation of multinucleated cells. 
Nuclei surrounded by a greater cytoplasmic volume were bigger that the ones 
surrounded by a smaller cytoplasmic volume. If these cells are subjected to 
ultracentrifugation and then allowed to divide, cells with a larger amount of 
cytoplasm adjusted the nuclear volume rapidly to re-establish a normal 
karyoplasmic ratio, where cells in which the nuclei were too big for the 
surrounding cytoplasmic volume, nuclear growth was arrested until the 
cytoplasm reached an optimal volume (Neumann and Nurse 2007).  
As well as soluble factors that can shuttle between cytoplasm and 
nucleoplasm also activation of oncogenes could potentially have an impact in 
nuclear size alteration. Throughout cancer progression several genes are 
repressed and activated due to the genomic instability of the cell, these genes 
could influence up or downregulation of proteins that can impact the stability 
of the nuclear architecture. A direct link between oncogenes and nuclear size 
regulation is not evident yet but the nuclear envelope interacts with several 
pathways, especially through lamin A/C interactions, that result altered during 
cancer progression. Lamin A/C for example interact directly with LAP2b, and 
both proteins can regulate pRB resulting in accumulation of 
hyperphosphorylated pRB, leading to delay in cell cycle (Johnson et al. 2004).  
Furthermore, downregulation of lamin A/C results in mislocalization and 
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proteasome degradation targeting of pRB, suggesting increase proliferation 
through the loss of the pRB checkpoint (Bell and Lammerding 2016). 
The nuclear envelope can interact also with b-catenin, modulating the 
Wnt/b-catenin signalling. Recent studies have proven direct interaction of 
Emerin with b-catenin, repressing its activity through negative regulation of 
nuclear accumulation (Markiewicz et al. 2006). Furthermore, also Nesprin 2 is 
able to interact with both a-catenin  and b-catenin and depletion of this protein 
lead to reduction of nuclear accumulation of b-catenin (Neumann et al. 2010), 
pointing to how the nuclear envelope is tightly interconnected in the regulation 
of different oncogenes pathways that could result in advantages for cancer 
cells.    
It is quite clear then that different cytoplasmic factors can influence nuclear 
volume by different mechanisms and abundance of particular proteins. It 
remains to be elucidated what all of these factors are and if they can be 
modulated to reduce aberrant alteration of the nuclear size in order to treat 
patients more effectively.  
 
1.6 Link between the NE and cancer 
 
 Although little is known about the majority of NETs, to determine their 
likelihood of contributing to cancer progression or metastasis, analysis of NETs 
identified in NE proteomic studies for changes in different tumour types using 
the TCGA cancer database (https://cancergenome.nih.gov) revealed that 
many tend to be lost or inappropriately expressed in a variety of tissue-specific 
tumour types (Fig 5B). The TCGA is a project funded by the NIH for the 
sequencing and identification of genetic mutations causing cancer. The project 
sequenced and determined gene copy number and SNPs alterations, among 
many other variations, in patients samples of around 20-25 types of different 
cancers. One example of tissue specific proteins altered in cancer is the NET, 
LPCAT3, a protein expressed relatively widely, but not in ovaries. Its 
expression profile changes drastically in certain cancer types, with it being 
strongly upregulated in ovarian cancer but down-regulated in lung cancer (Fig 
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5C) (de Las Heras, Batrakou, and Schirmer 2013; de Las Heras and Schirmer 
2014). The tissue-specific differences characteristic of each tumour type may 
be at least partly explained by such changes in these tissue specific NETs 
during cancer progression.  
Another interesting example is that analysis of patient sequences in the 
TCGA cancer database revealed relatively high mutation frequencies with 
mutations in SYNE1 (encoding nesprin 1) reaching 26% in Stomach 
Adenocarcinoma, 24% in Skin Cutaneous Melanoma and 21% in Colon 
Adenocarcinoma. Other nesprins were also highly mutated in specific tumour 
types with SYNE2 (encoding nesprin 2) mutated in 20% of Liver Hepatocellular 
Carcinoma patients and more than 10% in at least four different cancer types. 
Interestingly, SYNE3 (encoding nesprin 3) was only highly mutated in 
Pancreatic Adenocarcinoma, at 24% of patients, with the next highest mutation 
frequency being at just 3% in Lung Adenocarcinoma, indicating considerable 
tissue-specificity even just amongst this protein family in its potential 
relationship to cancer. Notably, several different cancers had much lower 
levels of mutations in SYNE/nesprin proteins, often as much as 100-fold lower 
(Fig 5A). 
 Given the alteration of different genes and expression of proteins at the 
NE, screening for nuclear size alterations caused by lost or gain of these 
proteins might bring more clarity to tissue specific phenotypes detected in 





cancer	 types.	 Accumulation	 of	mutations	 in	 SYNE	 genes	 differs	 for	 each	 gene	 and	 for	 each	 tumour	 type.	 For	
example,	SYNE3	is	only	highly	mutated	in	Pancreatic	Adenocarcinoma	while	SYNE1	and	SYNE2	are	highly	mutated	
in	a	larger,	but	partly	distinct,	set	of	cancers.	Blca:	Bladder	Urothelial	Carcinoma;	Brca:	Breast	Invasive	Carcinoma;	
Coadread:	 Colon	 Adenocarcinoma;	 Gmb:	 Glioblastoma	 Multiforme;	 Hnsc:	 Head	 and	 Neck	 Squamous	 Cell	
Carcinoma;	Kich:	 Kidney	Chromophobe;	Kirc:	 Kidney	Renal	Clear	Cell	 Carcinoma;	 Luad:	 Lung	Adenocarcinoma;	









1.7 Potential mechanism of nuclear size regulation 
	
 As the NE is the outer shell that delimits the nucleus, many NE proteins 
might be limiting or influencing nuclear size alterations. These range from NPC 
transport functions to the lamin scaffolding to the connections to cytoplasmic 
filaments or proteins involved in lipid synthesis. Such proteins could be under 
a feedback regulatory mechanism for amounts synthesized or a timed 
mechanism that links nuclear size increases during the cell cycle to the length 
of a particular stage. Thus changes to gene expression and cell proliferation 
in cancer cells might underlie nuclear size changes. Notably, such changes in 
gene expression could themselves be influenced by nuclear size changes if 
this alters the relative amount of peripheral heterochromatin and gene 
silencing (Fig 6A). Some of the NETs have been shown to be able to reposition 
entire chromosome from an active state to the NE periphery where the genes 
get repressed (De Las Heras et al. 2017; Zuleger et al. 2013). Examples of 
these NETs are NET39, WFS1 and TAPBPL. These proteins are able to 
reposition chromosome 5 from the interior to the periphery of the nucleus, 
leading to inactivation of important genes for muscle development (Robson et 
al. 2016). It results clear that loss of proteins with this ability to anchor genes 
to a heterochromatin environment during cancer progression can lead to 
alteration of genes that regulate nuclear size and can therefore drastically 
influence the nuclear architecture. At the same time an abnormal alteration of 
the nuclear size without a feedback mechanism that can re-supply the 
physiological amount of protein at the NE can lead to less anchor points at the 
membrane and therefore to the release of a gene that would be normally 
repressed.     
 It is also possible that a completely independent sensor mechanism 
maintains the karyoplasmic ratio, for example sensing a change in tension 
between chromatin contacts and the NE on one side and connections with 
cytoplasmic filaments on the other. If this were the case then changes in 
cancer cells to NE-chromatin or NE-cytoplasmic filament interactions might 
underlie nuclear size changes. For example alteration of key proteins in the 
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LINC complex using a dominant-negative nesprin mutant led to nuclear size 
defects (Lu et al. 2012) and knockout mice lacking the Nesprin-2 giant isoform 
resulted in thickening of the dermis due to increased nuclear size (Luke et al. 
2008a). Such changes could also explain nuclear shape changes and NE 
blebbing that often accompanies the size changes in cancer cells (Fig 6B). 
Thus, in theory, alteration of the expression of nesprins in cancer could 
lead to changes in cytoskeleton and nuclear stiffness and elasticity, nuclear 
shape, and nuclear size and accordingly enable extravasation of tumour cells 
during metastatic spread 
 A third mechanism might involve post-translational modifications, 
particularly phosphorylation cascades that often go awry in cancer cells. Such 
modifications are important for both the stability of the lamin polymer and for 
NE-chromatin interactions. Indeed, mitotic disassembly of the lamin polymer 
is coupled with hyperphosphorylation of both lamins and NETs to break the 





regulating	nuclear	 size.	Reduction	of	 scaffolding	proteins	 such	as	 lamins	 through	gene	misregulation	could	be	
limiting	for	nuclear	size	increases	(left).	At	the	same	time,	up-regulation	of	such	proteins	could	promote	nuclear	








1.8 Advantages of nuclear size alteration in cancer 
	
		 The central conundrum that faces us is how can both nuclear size 
increases and decreases promote increased metastasis in different tumour 
types? A smaller nuclear size could obviously convey the advantage of being 
able to squeeze through junctions between cells during invasion of other 
tissues, but one might expect that a larger nuclear size would hinder this. This 
apparent contradiction might be resolved when considering that the NE 
connects to both cytoplasmic filaments on one side and chromatin on the other 
side. The largest molecules in the cell are the chromosomes that reach 
gigadalton masses and dwarf even actin stress fibers in total size. Several 
studies have shown that chromatin connections to the NE are similarly 
important as the intermediate filament lamin polymer for nuclear shape and 
mechanical stability (Thorpe and Charpentier 2017; Thorpe and Lee 2017). If 
the increase in nuclear size reduces the strength of heterochromatin 
interactions with the NE then this could enable an even larger nucleus to distort 
and squeeze between cell-cell junctions for invasion (Fig. 7). At the same time, 
there might be an even simpler explanation if both nuclear size increases and 
decreases are associated with changes in cytoplasmic filament connections 
that facilitate cell migration. The findings that altering levels of both lamins and 
LINC components affects cell migration in wound healing assays (Lee et al. 
2007) indicates the likelihood of this possibility. Furthermore, tissue-specific 
NETs that contribute to lamin-LINC-cytoplasmic filament connections could 
confer the tumour-type specificity for this nexus. Importantly, such disruption 
of the even larger chromatin-lamin-LINC-cytoplasmic filament nexus could 
additionally weaken the mechanical stability of the nucleus to explain the 
changes in nuclear shape including blebbing that often accompanies nuclear 
size changes (Fig. 7). 
 A larger nuclear size accompanied by a reduced heterochromatin 
interaction with the nuclear periphery might also enable faster proliferation for 
metastasis, not just through changes in gene expression or post-translational 
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modifications as mentioned above, but also by having less late-replicating 
peripheral heterochromatin and having to break fewer genome-NE contacts 
when replicating the genome. Changes in such contacts could also influence 
overall genome stability whether due to loss of lamin A or a tissue-specific 
NET. Notably, lamins also bind pRb and can affect proliferation by 
sequestering or releasing pRb (Van Berlo et al. 2005; Johnson et al. 2004). 
Similarly several NETs have been shown to bind transcriptional regulators and 
Smads for example are sequestered by the NET MAN1 away from target 
genes in the nucleoplasm such that altering MAN1 can yield bone disorders 
(Ishimura et al. 2006; Osada 2003; Pan et al. 2005). Thus both lamins and 
tissue-specific NETs can influence metastasis through effects on proliferation 






more	 readily	 squeeze	 between	 tight	 cell–cell	 junctions	 to	 invade	 a	 tissue	 (top).	 If	 a	 bigger	 nucleus	 has	 fewer	
interactions	with	chromatin	and/or	more	euchromatin,	this	might	enable	greater	malleability	for	the	nucleus	to	
change	 shape	 to	 squeeze	 between	 cell–cell	 junctions	 (bottom).	 B.	 	 Alterations	 of	 lamin	 and	 LINC	 complex	
connections.	Loss	of	lamins	can	weaken	the	mechanical	properties	of	the	nucleus,	allowing	easier	deformability	in	
squeezing	through	cell–cell	junctions	and	so	increasing	metastasis	(upper	panels).	The	connections	between	the	
nucleoskeleton	 and	 cytoplasmic	 filaments	 also	 affect	 cell	 migration	 in	 wound	 healing	 assays,	 and	 so,	 their	
disruption	could	result	in	an	increased	speed	for	migration	of	the	cancer	cell	(bottom	panels).	Note	that	in	this	




1.9 Aims and hypothesis  
 
Regulation of nuclear size and shape is a complex mechanism that may 
be important in many aspect of cancer progression, from diagnosis to potential 
alteration to gene expression favouring more metastatic tumours. As these 
alterations are characteristic of different tumour types the efforts to identify the 
factors that direct the process of maintaining a normal nuclear size and shape 
have been focusing on communal structures such as lamins or the LINC 
complex, and not taking into consideration the tissue specificity of phenotypes. 
NETs have been shown to be tissue specific, or at least tissue restricted, and 
with effects in genome repositioning highly dependent of the tissue where they 
are expressed. Therefore, NETs can be one of the key players in conferring 
the tissue specific alterations found in different tumour types. 
Targeting proteins involved in nuclear size regulation can result in better 
outcomes for patients, and provide valuable new targets for new drugs to be 
added to chemotherapy regimens. Importantly the tissue specificity should 
focus toxicity and thus reduce some of the side effects typical in chemotherapy 
regimens. For this reason, we are also interested in identifying potential small 
molecules that are able to alter nuclear size, in order to restore normal size, 
that can be used in conjunction with other drugs to reduce tumour size or slow 
down generation of metastasis.  
 
 
1.9.1 Pervious work towards understanding nuclear size regulation  
 
 In line with this hypothesis, a previous MSc student and honours student 
have screened for NETs altering the nuclear size through transient transfection 
of some of the constructs used in this study. A 2D nuclear size screen of 10 
different NETs was performed analysing the mid-cross sectional area of the 
nucleus in an asynchronous HT1080 population. This screen identified 4 
proteins with potential nuclear size regulation, namely NKP9, NET50, NET26 
and Emerin (Bernard Hörmann Master thesis) (Fig 8). To have more precise 
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and robust measurements and overcome the problem of different nuclear sizes 
across an asynchronous population, a more in depth 3D analysis was carried 
out in a double thymidine blocked population, focusing on the positive hits 
identified in the first screen. NETs were transiently expressed in the 
synchronised culture and volume reconstruction of the whole nucleus was 
extrapolated from deconvolved z-stack series. This analysis revealed that 
emerin, NKP9 and NET50 have effects on the nuclear size and may be active 
in the nuclear size regulation (Edward Jarman Honours project) (Fig 8). Based 
on this preliminary data we decided to screen for more NETs to potentially 
identify tissue specific nuclear size regulators that can be involved in or 
responsible for the phenotypes detected in different type of cancers and also 
screen for small molecules affecting nuclear size. This is the work that will be 













2. Material and methods 	
2.1 Materials  
	
2.1.1 Bacterial strains and genotypes  
 
DH5alpha 
F– endA1 glnV44 thi1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM1
5 Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ– 
 
Sure2   
endA1 glnV44 thi-1 gyrA96 relA1 lac recB recJ sbcC umuC::Tn5 uvrC e14- 
Δ(mcrCB-hsdSMR-mrr)171 F'[ proAB+ lacIq lacZΔM15 Tn10 Amy CmR] 
 
PLys-S   
F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 [lacI lacUV5-
T7p07 ind1 sam7 nin5]) [malB+]K-12(λS) pLysS[T7p20 orip15A](CmR) 
 
TOP10   
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 
araD139 Δ(ara-leu)7697 galE15 galK16 rpsL(StrR) endA1 λ- 
 
Rosetta (DE3)pLysS 
E. coli str. B F– ompT gal dcm lon? hsdSB(rB–mB–) λ(DE3 [lacI lacUV5-
T7p07 ind1 sam7 nin5]) [malB+]K-12(λS) 
pLysSRARE[T7p20 ileX argU thrU tyrU glyT thrT argW metT leuW proL orip1
5A](CmR) 
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Buffer/Solution name Composition  
 
Luria Bertani (LB) medium 
1% Tryptone 
0.5% yeast extract 
200 mM NaCl 
 
 
Super Optimal broth 
with Catabolite repression (SOC) 
  
2% tryptone  
0.5%  Yeast extract  
10mM NaCl  




Phosphate saline buffer (PBS) 
50 mM potassium phosphate 
150 mM NaCl; pH 7.4 
 
Alkaline Lysis Buffer 1 
 
50 mM glucose 
10 mM EDTA 
25 mM Tris (pH 8.0) 
 
Alkaline Lysis Buffer 2 
 
0.2 N NaOH 
1% SDS 
Alkaline Lysis Buffer 3 
 
3 M KOAc (pH 6.0) 
Dulbecco's Modified Eagle 
Medium  
(DMEM) 




Roswell Park Memorial Institute 
medium (RPMI) 1640 




Opti-MEM Reduced Serum  Medium 
Gibco, 31985062 
TAE 40 mM Tris-acetate  
1 mM EDTA  
Protein Running Buffer (SDS-
Page) 
25 mM Tris pH 8.3  
35 mM SDS 
150 mM NaCl 




2.1.3 Primary antibodies  
 







NET50/DHRS7 Rabbit  1:50 1:1000 38 kDa Abcam 
ab156021 
Lamin A/C Rabbit 1:50 1:1000 70 kDa Schirmer, 
2001 
SUN1 Rabbit 1:50 N/A N/A Atlas 
antibodies 
HPA 008346 
GFP Rabbit  1:100 1:200 25 kDa Generated by 
Dizmity 
Batrakou 
RFP Rabbit 1:100 1:200 25 kDa Generated by 
Dizmity 
Batrakou 
a Tubulin  Mouse 1:500 1:2000 50 kDa Sigma T6074-
200UL 
g Tubulin Goat 1:500 N/A N/A Sigma T6557 
Emerin  Rabbit 1:50 N/A N/A Glenn Morris 
Phospho-
Stat3 
Rabbit  N/A N/A N/A Merck 
RAB0447 
Pan-Stat3 N/A N/A N/A N/A Merck 
RAB0447 







2.1.4 Secondary antibodies 
  
Antigens targets, source and dilution of antibody used in this study are 
summarised in table 3. To reduce cross-reactivity in double staining all 
secondary antibodies were raised in donkey against mouse or rabbit IgG. To 
reduce signal:noise ratios conjugants to Alexa Fluor® dyes (Molecular Probes, 
Invitrogen) were used. For Western Blotting, fluorescence labelled IRDye® 
(Licor) anti-mouse or anti-rabbit were used. 
 
 
Table 3 Secondary antibody used in this study   
Antibody  Host  Dye  Dilution  Source 
Anti-mouse  Donkey  Alexa 488 1:500 Invitrogen 
(A21202)  
 
Anti-rabbit Donkey Alexa 488 1:500 Invitrogen 
(A21206)  
 
Anti-mouse  Donkey Alexa 568 1:500 Invitrogen 
(A10037)  
 
Anti-rabbit  Donkey Alexa 568 1:500 Invitrogen 
(A10042)  
 
Anti-rabbit  Donkey Alexa 630 1:500 Invitrogen 
(A21202)  
 
Anti-mouse  Donkey IRDye® 
800CW 
1.1000 Licor (926-32212) 
 
Anti-rabbit  Donkey IRDye® 
800CW 
1:1000 Licor (926-32213) 
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Anti-mouse Donkey  IRDye® 
680CW 
1:1000 Licor (926-68073) 
 
Anti-rabbit Donkey  IRDye® 
680CW 




2.1.4 Mammalian cells  
 
Human fibrosarcoma cell line HT1080, human cervix adenocarcinoma 
cell line HeLa, human prostate carcinoma cell line PC3, human colorectal 
carcinoma cell line HCT116 and human non-small cell lung cancer cell line 
H1299 were purchased from the American Type Culture Collection (ATCC) 
collection. Several of these lines were modified to express RFP or other 
markers as described in the table below. 
  
Table	4	Cell	lines	used	in	this	study		
Cell Line Type of cancer  Source  Reporter  











PC3 cell line 
Monomeric 
RFP 
PC3-LUC Human prostate 
carcinoma 
Derived from 

































































2.1.5 Chemical compounds  
 
Identified compounds in the screens were purchased in larger quantities 
from Sigma-Aldrich or CarboSynth (table 5) and were diluted to a 10 mM stock 
concentration in DMSO and used at the concentration reported in the figures. 
 
Table	5	Chemical	compinds	used	in	this	study.	
Compound name Source  CAS number Reference 
Oxyphenbutazone 
 
Sigma-Aldrich 129-20-4 SML0540 
Paroxetine 
Hydrocloride 
Sigma-Aldrich 110429-35-1 PHR1804 
	 45	
Parbendazole Sigma-Aldrich 14255-87-9 32438 
 
Piperlongumine Sigma-Aldrich 20069-09-4 SML0221 
 











2.2 DNA procedures 
 
2.2.1 Plasmid DNA sequencing  
 
All plasmids used in this study were verified by sequencing. The 
sequencing was performed by the GenePool facility (University of Edinburgh) 
using standard Sanger sequencing techniques. Sequence chromatograms 
were analysed and cross-referenced with the software Lasergene (DNA Star). 
A full list of plasmids used in this study is reported in the appendix.  
 
2.2.2 Cloning and site direct mutagenesis 
 
Cloning was performed using general restriction enzyme digest and 
ligation cloning protocols or with the Gibson methodology. All restriction 
endonucleases II were from the FastDigest system (Fermentas), Phusion DNA 
polymerase and DNA ligase from New England BioLabs.   
The Gibson Assembly Mix was produced in house or via the commercial 
NEBuilder Assembly Kit (New England BioLabs) following the manufacturer's 
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recommendations. Briefly, between 50 and 100 ng of vector, depending on the 
number of inserts used in the reaction mix, were incubated with 0.2-0.5 pmol 
of inserts at 50°C for 1 h and transformed in DH5alpha cells after DpnI 
digestion.  
Generation of the expression plasmids for mammalian protein 
expression in bacteria were performed with the BioBrick cloning systems. 
Inserts were amplified with the addition of overhangs (Forward: 5’- 
TACTTCCCAATCCAATGCA; Reverse: 5’- TTATTCACTTCCAATTTATTA). 
The backbone vector was linearized with Ssp I restriction endonuclease II 
enzyme (NEB) and processed with T4 polymerase (NEB) in presence of 
dGTP. The inserts were processed in the same reaction mix but in the 
presence of dCTP. Vector and inserts were annealed at RT for 10 min, 
transformed and plated in XL1Blue bacteria in the presence of selection 
antibiotics. 
Site direct mutagenesis was performed according to the manufacturer’s 
recommendations for the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent) with primers designed with the Agilent on-line tool 
(https://www.genomics.agilent.com/). 4 μl of the PCR amplification product 
were transformed in TOP10 bacteria via heat shock, after DpnI digestion for 1 
h, and spread on plates with the opportune antibiotic resistance. 
Extraction and purification of plasmid DNA was performed either with standard 
alkaline extraction (Buffer 1, buffer 2 and buffer 3) or with QIAprep Spin 
Miniprep Kit (Qiagen).  
 
 
2.3 Mammalian cell culture 
 
2.3.1 Mammalian cell lines and maintenance  
 
HT1080, HeLa, PC3, H1299, HCT116 and their derivatives (see 
Generation of stable cell lines) cell lines were maintained in Dulbecco's 
Modified Eagle Medium (Lonza) containing 4.5 g/L glucose and L-Glutamine 
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and supplemented with 10% FBS (HyClone). Human prostate carcinoma cell 
line LNCaP was maintained in Roswell Park Memorial Institute (RPMI) 1640 
Medium containing 4.5 g/L glucose and L-Glutamine and supplemented with 
10% FBS (HyClone). All cell lines were maintained at 37°C, 5% CO2 in a 
humidified environment.  
For experiments where estradiol or estradiol propionate was used cells were 
maintained in the same condition as above with the substitution of normal FBS 
with 10% charcoal stripped FBS to deplete hormones intrinsically present in 
normal FBS. This enables a more clean analysis in hormone experiments with 
NET50 such that the drug being analysed is not be masked by a mixture of 
unknown hormones from serum.  
 
2.3.2 Generation of stable cell lines  
 
PC3.H2B.mRFP, HCT116.H2B.mRFP and H1299.H2B.mRFP were 
generated with co-transfection of linearized H2B.mRFP.BL vector and pToI2 
encoding for transposase with JetPrime (PolyPlus transfection) transfection 
reagent, following the manufacturer’s directions. 24 h post transfection the 
medium was replaced with medium containing 8 μg/ml blasticidin (Thermo 
Fisher Scientific) to select stable integrated transfectants.  
After stable selection and amplification cells were FACS sorted for the brighter 
mRFP population that retained normal morphology and further amplified 
before storage in liquid nitrogen.   
For the generation of PC3.LUC reporter cells, the progenitor cells were 
seeded at a concentration of 105 cells/well in a standard tissue culture 6 well 
plate the night before virus transduction. Cells were incubated with 0.5ml 
lentiviruses carrying the plasmid pHIV-Luc-ZsGreen1, 0.5 ml of standard 
medium and 0.1 μl of polybrene (stock 10mg/ml,) and allowed to react 
overnight. Medium was changed the following morning and cells were grown 
for 48 h to allow expression of the construct and then FACS sorted for GFP 




2.3.3 Transfection procedures  
 
Transfections were performed with Fugene 6 (Promega) or 
Lipofectamine 2000 (Life technologies) following the manufacturer's 
recommendations. In short for standard transfections, ~106 cells were 
transfected in suspension with 1.6 mg of the desired plasmid. Transfection 
medium was replaced with full fresh medium after 16 h to avoid excessive cell 
death. Cells were allowed at least 48 h for expression of the construct before 
follow up procedures. 
 
2.3.4 siRNA transfections 
 
 For siRNA transfection 1.5x106 cells were seeded the day before 
transfection and allowed to attach to 6 well plates. The following morning 25 
pm or 100 pmol of siRNA was mixed with 4 μl of JetPrime (PolyPlus 
transfection) transfection reagent in 200 μl of JetPrime buffer and added to the 
cells. Cells were allowed 72 h before analysis of protein levels by Western blot 




















2.3.5 Cell viability and Apoptosis/Necrosis assays  
 
For cell viability assays cells were seeded onto PE96 plates 
(PerkinElmer) at a concentration of 5,000 cells/well in a final volume of 100 μl 
before compound addition. Growing media was replaced with media 
containing six serial dilutions of each compound and cells were allowed to 
grow for either 6 or 36 h. 10 μl Alamar blue (Thermo Fisher) reagent was added 
on each single well and allowed to react for 3 hrs prior to taking an absorbance 
reading at 530 nm or a fluorescence reading with excitation at 560 nm and 
emission at 590 nm on a microplate reader (JASCO V-550). 
For apoptosis and necrosis analysis cells were incubated with each 
compound at a concentration of 10μM in standard 6 well tissue culture plates. 
Around 106 cells were counted, washed with ice cold PBS and stained with 5 
μl of the Annexin V apoptosis marker conjugate with the 647 Alexafluor 
chromophore (Thermo Fisher Scientific) and 5μl of 50μg/ml Propidium Iodide 
(Biotium) for cell death detection, in 10 mM HEPES, 140 mM NaCl, and 2.5 
mM CaCl2, pH 7.4 for 15 min before FACS analysis. The 647 nm signal was 
used for detection of early stages of apoptosis as cells are not permeable to 
propidium iodide at this stage. Late stage apoptosis was detected by presence 
of both of the markers and necrotic cells by the presence of propidium iodide 
signal only.  
 
2.3.6 Wound Healing assays 
	
For wound healing assays around 25,000 cells per well were seeded on 
a BioEssence 96 LockView well plate (BioEssence) the night prior to wound 
formation. The cell monolayer was scratched with the IncuCyte® 
WoundMaker, that simultaneously makes equivalently-sized scratch wounds 
in the monolayer in all wells, and medium replaced with compounds containing 
medium supplemented with 1% FBS to induce cell migration and reduce cell 
proliferation. Plates were placed in the IncuCyte® incubator and imaged in 
bright field every 3 h for 48 h. Analysis of the wound closure time were 
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performed with an automated script provided by BioEssence determining the 
percentage of wound closure. The script allows masking of the wound area 
due to a different light reflection determining the presence and absence of cells 
and therefore percentages of wound closure. As the images are taken within 
a short period of time, the script allows the possibility of tracking single cells to 
discriminate between migration and cell division that could alter the final read 
out. The experiments in this study were conducted in 1% FBS to avoid this 
erroneous measurements and therefore the tracking of cell movements was 
not analysed. 
  
2.3 Protein procedures  
	
2.3.1 SDS page and Western Blotting  
 
Protein lysates were analysed on 12-15% SDS- polyacrylamide gels 
casted using the BioRad mini PROTEAN ® Handcast system (BioRad). The 
resolving gel at the required percentage (10 - 15 %) was prepared and poured 
in between 1 mm glass plates. Stacking gel with 10 or 15 well combs was 
layered on top of the resolving gel once set. Protein samples were mixed with 
SDS loading dye, boiled for 1 min at 95°C before loading, along with 5 μl of 
protein molecular weight marker (Pierce). SDS-PAGE was run for 10 min at 
100 Volts to pack proteins in one band and allow them to migrate through the 
separating gel at the same time, obtaining the optimal resolution of different 
size proteins. The gel was run continuously at 150 volts until the dye front 
reached the bottom of the SDS-PAGE. 
            The visualisation of proteins in the gel was achieved by staining with 
Coomassie stain using a Thermo Scientific™ Pierce™ Power Stainer (Thermo 
Scientific, 2011). According to the manufacturer guidelines, gels were boiled 
in water and then sandwiched in between 4 pieces of Whatman paper, soaked 
in either destain and Coomassie staining solution. For subsequent destaining 
procedures, the gel was places in water with a piece of tissue, to absorb the 
residual staining solution. 
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 For Western blotting the proteins were transferred without prior 
Coomassie staining onto PVDF membranes with a pore size 0.45 μm 
(Millipore, IPFL00010) using a Thermo Scientific™ Pierce™ Power 
Stainer (Thermo Scientific, 2011). The membrane was blocked with 4% non 
fat milk in PBS with 1% Tween 20 for 1 h to saturate potential reactive epitopes, 
and subsequently incubated with primary antibodies against the target for 1h. 
Signals were detected with InfraRed Dye (LiCor) conjugated secondary 
antibody after incubation for 20 min. InfraRed Dye bands were scanned on a 
LiCor scanner and analysed using Odyssey software.  
 
2.4 Fluorescence procedures 
 
2.4.1 Immunofluorescence microscopy  
 
For general antibody staining, after 48 h post transfection cells were 
directly fixed either for 7 min in 4% formaldehyde or for 10 min in ice cold 100% 
methanol at -20°C.  Formaldehyde-fixed cells were permeabilised for 7 min in 
0.2% Triton X-100 (Sigma) and blocked with 4% BSA (PAA laboratories, 
GmbH) in PBS and incubated for 1 h at RT with relevant antibodies. DNA was 
visualized with DAPI (Biotium) at a final concentration of 4 µg/ml and coverslips 
mounted in Vectashield (VectorLabs).  
For protein topology analysis, transfected cells were seeded onto Ø 13 mm 
coverslips 48 h prior to fixation with 4% formaldehyde for 7 min. Coverslips 
were placed on an ice-cold metal block and treated with 150 μg/ml Digitonin 
(Sigma) in PBS was added for 7 min. This digitonin concentration was chosen 
as it allowed permeabilization of the plasma membrane but not of the nuclear 
membrane for the cell line used for this experiment in a previous titration of the 
frozen and aliquoted digitonin prep. Control coverslips were permeabilized 
with 0.2% Triton X-100 for 7 min. All coverslips were washed in ice-cold PBS 
and blocked with 4% BSA for at least 20min. Primary antibodies against either 
GFP or RFP were incubated for 40min and appropriate fluorophore-
conjugated secondary antibodies were incubated for 20min at RT with DAPI. 
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Images were obtained using a Nikon TE-2000 microscope equipped 
with a 1.45 NA 100x objective, Sedat quad filter set and CoolSnapHQ High 
Speed Monochrome charge-coupled device camera (Photometrics) connected 
to a PC running Metamorph software. Images were deconvolved with the 
AutoQuant X3 software (Media Cybernetics) and 3D iso-surface volume 
reconstructions were generated with 3D image Pro (Media Cybernetics).  
 
2.5 Screening procedures  
  
2.5.1 Opera High content screening platform  
 
The Opera® high content screen platform (Perkin Elmer) is an 
automated spinning disk fluorescence confocal microscope for plate imaging. 
The characteristics (lasers, objectives and main optical configuration) of this 
platform are listed below (Table 7-8, Figure 9). The platform works in the native 
Acapella software that allows the set-up of the laser lines to use, number of 
fields of view per well, focus point, power and exposure parameters for each 
laser. Images can be analysed during imaging or after the imaging process 
with the pre-set or adapted scripts. The Opera can be couple with a robotic 
arm allowing full automation of entire screens. The robotic arm moves plates 
form a physical stack into the imaging unit allowing unique identification of 





Table	7	Laser characteristics on the OPERA High content platform.  
	
Laser Wavelength Laser type 
Blue 488nm Solid state laser 
Green/Yellow 561nm Laser diode 
Red 640nm Laser diode 
Violet 445nm Laser diode 
UV/Vis 350-680nm Xe-lamp with 
monochromator 
 












0.45 0.7 0.9 1.2 
Working 
distance 
6.9mm 0.6mm 0.16mm 0.28mm 
Field of view 430 x 345 
μm2 
430 x 345 
μm2 
215 x 173 
μm2 













2.5.2 Compound screening  
 
For compound screening PC3 H2B.RFP, HCT116 H2B.RFP and H1299 
H2B.RFP cells were seeded onto PE96 plates (PerkinElmer) at a 
concentration of 5,000 cells/well in a final volume of 99 μl at 14 h before 
compound addition. 1 μl of each library compound was added from 96 well 
stock plates using the Biomek automated liquid handler (Beckman) robotics 
platform or manually. Cells were incubated 6 h or 36 h before fixation with a 
final concentration of 4% PFA for 15 min. 50μl HCS CellMask Deep Red 0.5X 
(Molecular Probes) was added to the fixed cells for 15min to stain for the 
plasma membrane and determine cell area. Wells were then washed with PBS 
3 times for 5 min. Plates were loaded onto the robotic unit in groups of 15 after 
being marked with specific barcodes used for identification of unique runs and 
imaged overnight. Each well was imaged with 20 random fields of view with a 
20X air objective, avoiding the edge of the well where cells accumulate for 
capillarity. The adapted Acapella script was run at the same time of imaging, 
generating masks in both channels (cytoplasm and nucleus area) and 
exported in a .txt file for subsequent analysis in MathLab (The Mathwork). 
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2.3.2 NETs screening 
 
For the NETs screen HeLa H2B.RFP, HeLa H2B.GFP and PC3 
H2B.RFP were seeded in PE96 well plates (Perkin Elmer) at a concentration 
of 2,500 cells/well in final volume of 100 μl the day before transfection.  Cells 
were incubated with 5 μl of a mixture of 400 ng and 0.75 μl of Fugene 
(Promega) (200 ng/well final DNA) for each plasmid the day of transfection and 
incubated 48h to allow at least one cell division after induction of expression 
of the exogenous NETs. Plates were fixed with 4% PFA for 15 min, washed 3 
times in PBS and maintained in 100 μl/well PBS at 4°C until analysis on the 
Opera. Plates were allowed to warm up at RT for at least 30 min before 
imaging to allow condensation to dry and imaged with 2 different laser 
exposition (488 nm and 561 nm laser lines) for each of the 20 fields of view 
per well with a 20X water immersion objective. An adapted Acapella script, 
wrote by Jan Wildenhain and Silvain Tollis, was subsequently run to identify 
transfected cells and determine nuclear area of transfected and untransfected 
cells.  
 
2.3.3 Compound Libraries  
 
The main library used in this work is the Prestwick Chemicals Library 
(PCL) that comprises 1280 compounds approved by different drug agencies 
(FDA, EMEA and other) exploring different therapeutic chemical spaces. A 
scheme of the EMA classification of the library is reported in figure 10. All 
compounds are diluted from a Master plate concentration of 1mM and used at 
10μM in each screen, with controls being DMSO. 
For the setup of the compound screening a single plate from the 
MicroSource Spectrum library (Discovery systems, Inc.) was used, with the 




Figure	 10	 European	 Medical	 Association	 (EMA)	 drug	 classification	 of	 the	 Prestwick	 Pre	 Approved	 library.	
(http://www.prestwickchemical.com)	
 
2.4 In vivo models  
	
2 million PC3-LUC cells for each tumour injection were mixed in a 1:1 
ratio with Matrigel (Corning) and subcutaneously inoculated into both flanks of 
6-week-old male nude mice (5 mice per group, Charles River). After 1 week, 
mice were randomized (average tumour size ∼30mm3 per group) and received 
15 mg/kg in 50 μl piperlongumine or 10% DMSO in physiological solution 
intraperitoneally 5 days per week, excluding the weekends, for 3 weeks. 
Tumour sizes were measured twice weekly with a calliper. Tumour volume is 
effected by a physiological reduction after 7-10 days after the injection due to 
Matrigel slowly dissolving while the tumour mass grows and replace the 
Matrigel volume.  
Tumours were collected and halved 2 h from the last injection and either 
snap frozen in liquid nitrogen for storage before ELISA assays or processed 




2.4.1 ELISA assays 
 
 ELISA assays for pSTAT3 and tSTAT3 (Sigma-Aldrich) and GAPDH 
(ThermoFisher) were preformed according with recommended manufacture 
procedures. Briefly, tumours were frozen in liquid nitrogen and reduced to 
powder. Tumours were lysated with the provided lysis buffer for 10 min at RT 
in an orbital shaker. Derbies were removed by centrifugation in a micro-
centrifuge at 13000 RPM for 15 min and surnatant was transferred in a clear 
tube. Total amount of proteins was detected by NanoDrop and diluted to reach 
a concentration of 0.05 mg/ml of protein. For GAPDH measurements 50 μl of 
each sample were incubated, in the provided 96 well-plate, with a 50:50 
mixture of capture and detection antibody and incubated, in agitation, for 1 h 
at RT. Wells were washed 3 times with 100 μl of washing buffer and 100 μl of 
detection reagent was add. Absorbance was read through a microplate reader 
at 450 nm after 15 min of incubation of the detection reagent. 
 For tSTAT3 and pSTAT3 cell lysates were incubated in a pre-coated 96 
well plate for 2.5 h. Primary antibody against tSTAT3 and biotinylated antibody 
against pSTAT3 were incubated for 1 h at RT in agitation; and secondary anti 
rabbit IgG coupled with HRP and HRP-streptavidin for 45 min at RT. TMB 
substrate solution was allowed to develop for 30 min at RT in agitation and 
reaction stopped prior absorbance reading at 450 nm.  
 
2.5 Statistics and Analysis  
 
2.5.1 High throughput analysis  
	
Individual cells and nuclei within each field of view were masked using 
the automated threshold-based detection algorithm built into the Opera device 
(aCapella scripting environment, Perkin Elmer). Specifically, intensity 
threshold filters, size filters, and morphological filters were used to filter out 
detection artefacts, multiple detection of single cell/nuclei or unique detection 
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of cell clusters. Individual cell output data, comprising nuclear size generated 
by masking the RFP channel, the cytoplasm size generated by subtracting the 
nucleus mask from the mask detected for the plasma membrane channel, and 
average signal intensities was saved as text files that were loaded in Matlab 
(The Mathworks) for further analysis. Of note, identical detection and filtering 
parameters were used in aCapella to identify cells and nuclei under all 
conditions to normalise different runs to the same baseline data analysis and 
prevent post-acquisition processing biases. Specifically, for each condition 
separately, the entire cell size distribution was analysed, the median size (M) 
was calculated along with the first and third size quartiles Q1 and Q3 
respectively. Following standard outlier removal procedures, detections with a 
size larger than the outlier threshold M+6*(Q3-M), considered most likely cell 
clusters, and the detections smaller than M-6*(M-Q1), considered cell derbies 
o artefacts, were filtered out. All DMSO control wells of a single plate were 
treated together in this step.  
 
2.5.2 Statistics  
 
Statistics for NET50 nuclear volume reconstruction, wound healing, 
viability assays and xenograft tumour analysis were generated in Prism 6 
(Graphpad) using the appropriate statistical test for each set of experiments 







3. Screening for compounds and NETs affecting 
nuclear size 
 
 3.1 Introduction  
 
Nuclear size and shape is altered in most types of cancer and 
commonly used as a diagnostic tool for staging and grading cancer. Although 
it is not yet tested whether these changes are a consequence of other factors 
that drive increased metastasis or if they themselves are the drivers, in the 
latter case they would make promising therapeutic targets. Thus, we sought to 
identify proteins that can regulate or affect these features in cancer as potential 
future targets. We focused on NETs because they are perfectly placed 
physically to mediate nuclear size changes. Moreover, many of these proteins 
are tissue specific and so if they are involved it could explain differences in 
nuclear size and shape changes that are characteristic for different tissue 
cancer types.  
Along with identification of key proteins for nuclear size regulation, we 
are interested in identifying small molecules that can correct defects of the 
nuclei and that can be potentially added to chemotherapy regimens to improve 
survival rates by reducing metastatic spread or other characteristics 
associated with nuclear size changes that could give tumour cells an 
advantage. This chapter will focus on the set up of high throughput screening 
for the identification of NETs or compounds that affect nuclear size. 
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3.2 Optimization of screening parameters 
 
 The idea for setting up a high throughput screening is the possibility to 
have several conditions that can be tested at the same time in a relative short 
time. The Opera confocal system allows to set up fully automated screens 
generating high resolution images in 96 or 384 well plate formats with up to 5 
different laser exposures. This greatly reduces times for screening a large 
number of conditions: our screens involve 50 different NET transfections and 
entire drug libraries and the screening for each individual replicate can be 
performed within weeks once assays are optimised. The idea of this project is 
to screen for NETs that can influence nuclear size, and separately for 
compounds that can alter or restore aberrant nuclear size and restore 
karyoplasmic ratio in different cancer types. Even though the OPERA 
screening and analysis are similar for the two screens, each of required setting 
up specific parameters due to the differences in cell treatments before the 
imaging process.    
 
3.3 Cell confluency and plating procedures  
 
There are several variables to be considered while setting up an 
automated phenotypic high-throughput screen. The first consideration is the 
number of cells plated on an optical 96 well plate. If the number of cells is too 
low, cells might suffer from lack of contacts with neighbouring cells. Another 
factor that can alter normal survival of cells is the surface substratum which 
can affect the growth rate of the culture in addition to the more important effects 
on the strength of cell-substratum contacts which affects cell spreading and so 
can make the visualization of the nuclear and cytoplasmic area much easier 
or harder to quantify. More importantly for this screen where the read out is 
nuclear size, too confluent cultures might underestimate the real nuclear size 
due to squeezing by adjacent cells so that cells cannot spread properly. 
Moreover, as the analyses are carried out by an automated script that relies 
on a clear distinction between background and cells, overly confluent cells can 
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be interpreted as a large single cell rather than a cluster, generating artefacts 
in the final output. To avoid these erroneous readings several cell plating 
concentrations were tested to identify the correct concentration to reproducibly 
achieve an optimal density for visualization after 48 hours post transfection, 
and two different types of plates were tested for optimal cell attachment, 
spreading, and growth. Perkin Elmer plates were chosen due to the more 
robust attachment of cells and less cell cytotoxicity, with cells being seeded at 
a concentration of 2,500 cells per well to reach optimal density for imaging at 
48 h post-transfection for the NETs screen and 5,000 cells per well for the 
compound screen.  
Power calculations were used to determine the minimum number of 
cells required to detect at least a nuclear size alteration of 20% (Eq. 1). Power 
calculations allow determination of the sample size with a specific power for 
the test knowing the mean value (μ) of the population and its standard 
deviation (σ2). The power of a test is defined as 1-β where β is a type II error, 
occurring when the hypothesis H0 is accepted when false. For both screens 
the minimum sample size is 400 cells with a power of β=0.80 and α=0.5. 
According to this power calculation, number of cells plated and parameters 
decided were sufficient to achieve the minimal number of analysed cells. 
 
3.4 Optimization of microscope objectives  
 
To optimise screening parameters for both screens we tested what type 
of objective could best balance speed of screening against resolution. The two 
objectives tested were air 20X and water 40X. Each of these objectives have 
their own pro and cons as the 20X allows for a faster screening as the field of 
view is greater, therefore less fields are required for a satisfactory number of 
cells to achieve statistical differences, considering that the cells are not 
synchronized for the screen so the total distributions will already be at least 2-
3 fold. The 40X allows a better resolution and definition of the nuclei imaged, 
but at the same time requires at least twice as many fields to be imaged, 
compared with a 20X objective. To perform the setup of the screen a single 
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plate from the Spectrum library was used to compare the two objectives. 
Analysis revealed that both the 20X air and 40X water objectives identify cells 
with significant changes to the N/C ratio, with no statistical significance 
between the two objectives. The effects of identified compounds are consistent 
in the replicates and between the 20X and the 40X objectives (Fig 11).  Using 
a 20X air objective and imaging 20 fields of view gave the best balance 
between time for imaging, with around 1h for each plate, and number of cells 










3.5 Transfection procedures optimization  
 
Another variable that may have a great impact in the NETs screen is 
the transfection procedure, as the aim is to find an optimal balance between 
transfection efficiency and cell death. Different liposome-based transfection 
reagents were tested, each with different ratios between plasmid DNA and 
cationic liposomes to identify the best compromise. One finding was that too 
much DNA in the medium generates cell death. Lipofectamine 2000 and 3000 
resulted in a too high cell toxicity to leave a sufficient number of cells for 
analysis to support robust statistics plus the high number of apoptotic cells 
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yielded a high percentage of misreads with the Acapella software which could 
not be effectively programmed to discount apoptotic cells. Effectine (Roche) 
and JetPrime (PolyPlus transfections) transfections resulted in less cell 
toxicity, but lower and comparable transfection efficiency between each other. 
Fugene6 in contrast had a higher transfection efficiency and less cell toxicity 
with a final concentration of 100 ng of plasmid DNA per well and so it was 
chosen to use for the screen.  
 
3.6 Screening for NETs altering nuclear size  
 
Once all the parameters had been optimised the NET screen was 
performed in duplicate with 2 technical replicate wells on each plate. 52 
different GFP expressing NETs were screened and for each plate a NLS-GFP 
control, carrying the SV40 large T-antigen sequence (PKKKRKV) was added 
so that the control both underwent the same transfection procedure and 
expressed a protein that gets into the nucleus but doesn’t affect the NE. An 
adapted Acapella script, reported in the appendix section, for detection of 
transfected cells was implemented. The script identifies transfected cells 
based on the GFP channel from NET-GFP transfected and measures nuclear 
size on the RFP channel based on the cell line stably expressing H2B-RFP 
and thus allowing the determination of nuclear size of both the transfected and 
untransfected cells within a population as an additional internal control for 
population drift across the experiment. The ratio between transfected and 
untransfected cells for all conditions was normalized against the NLS-GFP 
control, and a threshold set for NETs with alteration of nuclear size greater 
than 20%. This identified a pool of NETs that might have regulatory effects on 








to	 detect	 alteration	 of	 nuclear	 size.	 A	 threshold	 of	 at	 least	 20%	 of	 nuclear	 size	 change	 has	 been	 applied,	
highlighting	 the	NETs	 having	 effects	 on	 nuclear	 size	when	 overexpressed,	 namely	 Emerin,	 SUN2,	 LBR,	NKP38,	
NKP91,	Tmem214,	NET82,	NET5,	NET77,	NET39,	NET29,	WFS1,	NET51	TAPBPL	and	NET99.	
 
Among the positive NETs from this screen, there were some of 
particular interest based on their known or predicted functions and known 
partners at the nuclear envelope. Emerin had already been identified prior to 
the high throughput screen by an Honours student in the Schirmer lab as a 
protein that increases nuclear size when overexpressed. This had been tested 
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both in 2D and using 3D reconstructions from deconvolved z-stacks (Hormann 
MSc Thesis and Jarman Honours Thesis). Interestingly it has been reported 
that nuclear size is altered in patients with Emery-Dreifuss muscular dystrophy 
caused by mutations in emerin (Shimojima et al. 2017). SUN2, a core protein 
of the LINC complex is of particular interest as SUN partner Nesprins have 
been previously liked to nuclear size regulation (Luke et al. 2008a). Finally, 
NET51 shows an interesting nuclear size alteration pattern as, depending on 
the part of the protein (N or C-terminus) tagged, the directionality of the change 
is the opposite. This could indicate the tag interfering with the activity of the 
protein, though which reflects the functional state is unclear. 
To verify that protein overexpression is not too high, as most of the 
NETs are driven from the strong CMV promoter, fluorescence levels were 
plotted against the nuclear sizes calculated. As shown in figure 13 most of the 
identified NETs with effects on nuclear size do not have high fluorescence 
levels, therefore reducing the possibility of artefacts deriving from a too strong 
expression. It is also an important control that fluorescence does not correlate 
with the nuclear size alteration, suggesting that some NETs may have a more 
fundamental role in regulating nuclear size than others and a lesser amount of 











The initial screen was performed in the HeLa cervical cancer epithelial 
cell line due to its generally high transfection efficiencies and the tendency for 
HeLa cells to have bigger nuclei that result in better detection by the script. 
However, the qualitative and quantitative differences in nuclear size changes 
in different tissue cancer types together with the tissue-specific expression of 
a majority of NETs suggested the possibility that different NETs might affect 
nuclear size only in particular cancer cell lines. Therefore, we also tested NET 
effects on nuclear size in prostate adenocarcinoma (PC3) and breast cancer 
(MCF7) cell lines. Transfection levels for the PC3 cell line were comparable 
with HeLa cells allowing a sufficient number of cells to be analysed for 
statistical significance based on the HeLa distributions, while for the MCF7 cell 
line transfection efficiency did not reach a satisfactory level. Analysis of the 
data from running the screen in the PC3 prostate cancer line revealed 
significant differences in the NETs with effects, indicating that NET effects on 
nuclear size are tissue specific. A few NETs had similar effects on both lines 
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(e.g. NET29 and WFS1), but the majority had effects on one cell line but not 
the other and vice versa. Interestingly, the proteins NET39/PPAPDC3 and LBR 
show alteration of nuclear size in two different directions in the two cell lines, 
with an increase of nuclear size for HeLa cells and a decrease in size for PC3 
cells, suggesting that the same protein if targeted in different pathologies might 
have opposing outcomes. 
Several other NETs with potential effect on nuclear size, as for example 
Nesprins, could be added on the screen but were left out due to their large 
cytoplasmic domain that would make the cloning of this proteins for this type 













3.6.1 NETs with effects on nuclear size have altered gene copy numbers in 
different cancers 
 
Some of the NETs identified with a potential role in nuclear size 
regulation have correlative changes in gene copy number in different cancer 
types according to the direction of size changes in each cancer. Analysis of 
data kindly provided by Erica Golemis at the Fox Chase Cancer Center 
(Philadelphia) identified at least 6 different NETs with such correlations in gene 
copy number: WFS1, NKP91/TMEM41A, TMEM214, NET77/SQTRM1, 
NET82/RHBDD1 and NET39/PPAPDC3. 
 For example, WFS1 overexpression increased nuclear size in HeLa 
cells. In 59% of lung squamous cell carcinoma patients, where a decrease in 
nuclear size correlates with worse prognosis, there is a hemizygous deletion 
of the gene encoding WFS1. In the opposite direction 41% of adrenocortical 
carcinoma patients, where bigger nuclei correlate with increased metastatic 
potential, exhibit a hemizygous amplification of the gene (table 9). Thus, the 
directionality of nuclear size changes in the cancers matches the NET 
expression and nuclear size directionality. These results suggest a correlation 
for tissue specificity of the same protein in different types of cancer, with 
directionality of nuclear size changes dependent of in which tissue the protein 






A pool of these NETs was transiently transfected in different tissue 
cancer cell lines: prostate cancer (PC3 cell line), breast cancer (MCF7 cell line) 
and adrenocortical carcinoma (HCT116 cell line), to further test if alteration of 
nuclear size is tissue specific. A widely expressed NET, Emerin, and a muscle 
tissue-restricted NET, NET39, were chosen to determine if tissue specificity of 
the expression could influence in different ways the nuclear size regulation. Z-
stacks were taken at 0.2 µm each step for each cell nucleus, but they were 
analysed in 2D by taking the nuclear area from the step with the largest area 
that should represent the middle of the nucleus. Effects on nuclear size are 






NET39) having a different directionality in the nuclear size alteration depending 
on the type of cancer (Fig 15).  
Emerin is a particular interesting NETs as is not tissue restricted and 
involved in the Emery-Dreyfuss muscular dystrophy (EMDM) (Brown et al. 
2008) and has been already implicated in alteration of the nuclear size in 
muscle cells (Shimojima et al. 2017). Moreover, this protein binds directly 
several transcriptional regulators and epigenetic remodellers, such HDAC3 
and HP1 (Demmerle et al. 2012; Rowat, Lammerding, and Ipsen 2006), 
therefore could influence several layers of nuclear size regulation and would 
be an interesting target to pursue further as target for development of new 
drugs.  
This result shows that NET-directed nuclear size regulation is highly 
tissue specific and dependant on other factors in the tissue background, 
arguing that further investigation of these tissue specific players for different 
cancer types might lead to approaches to increase the effectiveness of 
treatments. 










3.7 Screening for compounds altering nuclear size  
 
Along with the identification of potential proteins regulating the nuclear 
size, this project aims at the identification of novel compounds that can induce 
nuclear size alteration. These new compounds can be used to restore defects 
in nuclear size and might be used as novel chemotherapeutic agents in the 
treatment of cancers. For this reason a high throughput screening of the 
Prestwick library was performed to identify potential new drugs affecting the 
nuclear size that have already been approved by different drug agencies (FDA 
and EMA).    
An adapted Acapella script, reported in the appendix, was used to 
determine the nuclear and cytoplasm areas. The nuclear area was measured 
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from the H2B-RFP staining and for the cytoplasmic staining all area within the 
delineated plasma membrane stain was first measured and then the nuclear 
area was subtracted. These two numbers were used to determine the 
karyoplasmic ratio for each cell in the images obtained. Over 3,000 cells were 
analysed for each condition and the distributions for the individual nuclear 
areas and karyoplasmic ratios were used to determine an average size and 
ratio for each condition. 
With the parameters decided for this pre-screen, we were able to detect 
even 20% nuclear size changes with statistical significance (p<0.001, 
Wilcoxson non-parametric test for matched pairs). However, there were a 
number of cases where false positives were detected due to apoptosis in the 
sample, therefore images of positive hits were manually checked for all 










3.7.1 Compounds altering the karyoplasmic ratio show tissue specificity   
 
The screen was performed in three different cell lines: PC3, HCT116 
and H1299. These three cell lines were chosen in order to both compare two 
lines with the same directionality for the nuclear size change correlating with 
worst prognosis and also compare lines where the directionality is opposite. 
For prostate and colorectal cancers (PC3 and HCT116 cell lines) increased 
nuclear size and volume correlate with higher grade tumours, where in lung 
cancer (H1299 cell line) a reduction of nuclear size is associated with higher 
tumour grades. For each cell line 2 time points were screened: 6 and 36 h. The 
6 h time point was chosen to identify early and fast effects of drugs and to be 
able to distinguish if a nuclear size change occurred independently of the cell 
dying  for compounds with high cytotoxicity. The 36 h time point was important 
to determine if a compound had a cytotoxic effect and also to allow cells to 
undergo at least one complete cell cycle in case the NE would need to be 
disassembled and reformed at the end of mitosis in order to achieve the 
change in nuclear size. The first screen was conducted in biological triplicates 
for the PC3 cell line to determine its reproducibility. Having observed that it 
was reasonably reproducible, with a 17% probability to obtain a false positive, 
the screen was then performed in duplicate for the remaining cell lines and 








The karyoplasmic ratio was assessed using two different metrics. First, 
single cell karyoplasmic ratio was calculated and then averaged over all cells 
of a given condition. Each plate carries two internal DMSO control columns 
used to for the average values of the control and each of the remaining wells 
treated individually as represent a single compound. The mean N/C ratio 
(together with the associated standard error on the mean, SEM) was then 
compared across conditions (Fig 18A). While such an analysis method is, in 
principle, sufficient to detect overall shifts in the N/C ratio distribution across a 
cell population, it might be insufficient to detect conditions that either mis-
regulate the N/C ratio (and therefore broaden N/C ratio distribution without 
affecting the mean value), or strongly affect the N/C ratio in a small percentage 
of the cells in a population. To complement the analysis of the mean N/C ratio, 
we proceeded with a second analysis designed to reveal how treatment with 







small N/C ratio. Specifically, we first assessed upper (M+3*(Q3-M)) and lower 
(M-3*(M-Q1)), threshold values of the N/C ratio using the median (M), first and 
third quartiles (Q1 and Q3) of the distribution for N/C ratios of in-plate DMSO 
controls. As expected, due to cell population variation and as the screen is 
performed with one fixed focus plane, there was a minor percentage (3-5% 
depending on plates) of those DMSO-treated control cells that displayed a N/C 
ratio beyond those thresholds. Then, for each compound well, we quantified 
the percentage of cells that displayed a N/C ratio beyond those control cells-
derived thresholds. Those fractions of cells with abnormally large or small N/C 
ratio are expected to increase upon a global shift of a N/C ratio distribution 
following compound treatment, but also to respond to either a broadening of 
the N/C ratio distribution (loss of N/C ratio regulation in most individual cells) 















One of the compounds able to alter the karyoplasmic ratio that is 
noticeable on the hit results is paclitaxel, also known as taxol, because this is 
one of the most used chemotherapeutic agents to treat different types of 
cancer (table 10). It has an antimitotic activity against cancer cells that can 
explain the alteration of nuclear size. Taxol, however, was not present as a hit 
at 36 hours of treatment due to the cytotoxicity effects on the cell lines. Another 
interesting compound was podophyllotoxin that has been shown to have 
effects on the growth of carcinoma cells, especially the PC3 cell line (Xu et al. 
2011). Many of the hits have previously been used to treat cancer, suggesting 
that targeting actively the karyoplasmic ratio in cancer could contribute 
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3.7.2 Nuclear size vs karyoplasmic ratio 
	
	
	 Data were also analysed to identify alteration of just the nuclear size as 
this is the main morphological alteration analysed by cytopathologists when 
staging and grading different cancer types. Results showed more compounds 
identified with the nuclear size as the parameter compared with analysing the 
hits for the karyoplasmic ratio, with 45% more hits identified for PC3, HCT116 
and H1299 for both the time points (Fig 19A). 
Comparing the hits that are above the threshold of a statistical 
significance analysing the nuclear size or the karyoplasmic ratio, it results that 
if nuclear size is chosen as the parameter for the detection of positive hits, 
more compounds are identified compared with karyoplasmic ratio analysis, 
with some of these compounds not having an effect on the karyoplasmic ratio 
at all (Fig 19B). This could be explained as the regulation of cytoplasmic and 
nucleoplasmic volume is a multi-variable and complex regulation, therefore 
identify drugs that influence most of the pathways to detect an effect is more 
difficult. Moreover, the data were analysed in the second methodology to 
identify compounds that either increase or decrease the nuclear size, allowing 
to generate a pool of compounds that can be interesting in the follow up 
experiments depending on the type of cancer considered. For example, drugs 
decreasing the nuclear size are more interesting for prostate cancer and 
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adrenocortical carcinoma where an increase of the nuclear size correlates with 
the worst prognosis. These drugs could be useful to restore the original nuclear 













3.7.3 Cluster analysis reveals classes of compounds altering nuclear size or 
the karyoplasmic ratio of cells  
	
 
 Data were also analysed by type of compound and their therapeutic 
group to identify if there is any correlation between nuclear size regulation and 
therapeutic group or the molecular targets of these compounds. Clustering 
analysis revealed that some therapeutic groups, such as adrenergic receptor 
antagonists or Na+/K+ ATPase inhibitors, tend to cluster together, leading to 
an increase of the nuclear size more in the H1299 cell line compared to the 
other cell lines. Other compounds instead have a wider effect on all the cell 
lines such as microtubule inhibitors or MAP kinase inhibitors (Fig 20A). For 
compounds specifically decreasing the nuclear size, 5-HT serotonin uptake 
and cyclo-oxygenase inhibitors affect the nuclear size in most of the cell lines 





increasing	nuclear	size.	Data	are	plotted	based	on	 the	 therapeutic	effects	of	 the	drugs	 in	 the	 library,	dark	 red	





 Interestingly, analysing the therapeutic groups clusters it results that 
some compounds can alter the nuclear size both in the nuclear size aspect 
and the karyoplasmic ratio (e.g. Na+/K+ ATPase and COX inhibitors and 
microtubule depolymerisation agents), where other compounds such as b-
adrenergic receptor inhibitors increase only the nuclear size with no effects on 
the karyoplasmic ratio, indicating an activity on the general scaling of the cells 
of those compounds (Fig 21).   
 
	
Figure	21	Comparison	of	nuclear	 size	and	karyoplasmic	 ratio	alteration	 in	 cluster	analysis.	Heat	map	of	 the	
cluster	analysis	for	nuclear	size	and	karyoplasmic	ratio	are	presented	side	by	side.	Data	in	blue	represent	reduction	




 Analysing compounds that affect nuclear size leading to an increase, 
and therefore potentially benefitting the lung cancer model (H1299 cell line) in 
re-establishing a normal and more physiological nucleus, we can identify some 
classes of compounds that have effects at the 6 h time point such as b-
adrenergic agonists and on the longer incubation at 36 h such as microtubule 
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polymerization inhibitors. Bronchodilatators and Na+/K+ ATPase inhibitors 
instead have an increased nuclear size effect on the H1299 cell line in both of 
the time points and therefore flag these classes of compounds as potentially 
interesting for follow up characterization.  
 For compounds decreasing nuclear size, and therefore potentially 
beneficial for cancers in which enlargement of the nuclear size correlates with 
worse prognosis such as prostate cancer (PC3 cell line) and adrenocortical 
carcinoma (HCT116 cell line), the classes of compounds that generated more 
hits are 5-HT serotonin uptake, cyclo-oxygenase inhibitors and microtubule 
depolymerisation agents, with a strong effect on both the nuclear size as well 
as the karyoplasmic ratio. These classes of compounds are the most 
promising for further analysis in these cancer types and could provide 
interesting compounds to be tested and translated into the clinic.   
   
3.8 Chapter summary  
 
As targeting nuclear size and shape in addition to already existing 
chemotherapy regimens could result in less aggressive/metastatic tumours, it 
is of particular interest to identify potential new protein targets and drugs and 
to understand the potential mechanisms and factors that lead to loss of nuclear 
size during cancer progression. In this chapter I analysed roughly 50 NETs for 
their ability to change nuclear size when overexpressed in different cell lines 
with a high throughput approach. The approach allowed the fast analysis of 
multiple proteins at the same time resulting in identification of 18 potential 
NETs that can now be further characterized in detail for their roles in nuclear 
size regulation. Although the screen benefited from several high-throughput 
aspects, it also had some drawbacks. Firstly, it is possible that some NETs 
were missed due to the difficulty in obtaining high transfection efficiencies in a 
96 well format. If the screen were to be repeated this could be overcome with 
the establishment of stable cell lines overexpressing each of the proteins 
analysed in this study, although their generation would be a large amount of 
work so that the cost-benefit ratio might not be very high. There also might 
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have been more NETs identified if we had performed knockdown of the NETs 
as well, and especially as in doing both we could have identified NETs where 
overexpression had one effect on nuclear size and knockdown had the 
opposing effect.  This was not done initially because, as transmembrane 
proteins, NETs we have targeted in the past do not tend to turn over as fast as 
soluble proteins and we have also had much lower success rates even with 
commercially designed siRNA pools than others report for soluble proteins in 
knocking NETs down. Therefore, the initial investment in the time to develop 
these reagents would have potentially limited outcomes in the timeframe of the 
PhD. This, however, would have definitely had a strong benefit as it would 
allow us to investigate what likely happens physiologically in cancers where 
NETs are downregulated as is often observed in the TGCA database for NETs. 
Now that CRISPR approaches are getting much more successful and efficient 
this would perhaps be an even better way of generating lines with different 
NET knockouts for a future screen. Another limitation on the screen is the use 
of a single plane to measure nuclear area as opposed to measuring volume 
from taking z-sections and generating 3D reconstructions. Nonetheless, to 
minimise this defect, the plane decided for the screen represented the middle 
plane section for all the cells and any error made was likely minimized by the 
high numbers of cells analysed. With the current screen configuration, positive 
hits can be subsequently tested in more detail with 3D volume reconstructions 
on a higher resolution microscope to prove or discard the NET influence in 
nuclear size regulation.  
The fact that in two different cell lines we observe different proteins 
affecting nuclear size is consistent with the idea that tissue specific effects 
seen in different cancers for nuclear size changes are due to functions of 
different pools of proteins differently expressed in each tissue. This argues 
that, instead of using more generalised drugs in chemotherapeutic procedures 
such as taxol, incorporating compounds with more tissue specific effects might 
be applied to reduce toxic side effects and produce a more effective response 
against a particular tumour type. If indeed tissue-specific NETs are responsible 
for nuclear size changes, the size changes contribute to the increased 
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metastasis, and drugs identified in the compound screen target those NETs, 
then this approach could work, though much groundwork is still needed to 
determine these points. Nonetheless, this interpretation is consistent with 
bioinformatics analysis of cancer genotypes in the TCGA database where the 
same NET had gene amplifications in one cancer type and loss in another that 
both corresponded to the nuclear size changes observed in culture for the NET 
effects. It is nonetheless important to remember that this analysis is on the 
gene copy number and the second allele could theoretically overcompensate 
at the protein level for the loss of one gene copy or alterations in the 
mechanism of protein clearance and degradation can compensate for aberrant 
amplification of a gene. However, in general the indication of differential 
alteration of gene numbers, for these specific proteins, is consistent with the 
idea of tissue specificity of phenotypes and alterations due to tissue-specific 
NETs with effects on nuclear size.   
Along with the identification of potential new proteins that can be used as 
targets to specifically restore normal nuclear size in cancer cells and thus 
potentially reduce aspects of the increased metastasis associated with the 
nuclear size defects, these screens identified several repurposed drugs that 
can also alter nuclear size. The choice of using a pre-approved drug library 
should allow for more rapid translation of the identified drugs into clinical 
studies. The results showed that targets of nuclear size alterations are tissue 
specific, with small or in some cases barely any overlap within compounds 
identified in different cell lines. Among the identified compounds there are 
some that are already being used as effective anti-tumour treatments or other 
drugs that alter the nuclear size for obvious reasons such as anti-mitotic or 
microtubule depolymerizing drugs. The success in compound identification 
suggests that nuclear size as a readout for larger chemical libraries could 
identify even higher specificity and affinity compounds for cancer treatments. 
No particular class of drug emerged as strongly predominant in the screen that 
would have led to focus future studies on a more specific class of compound, 
but any of the identified compounds could be studied individually for changes 
in effectiveness with slight chemical modifications. This idea will be of interest 
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with some experiments in the next chapter where some of the strong and 











The idea that targeting nuclear size might be beneficial for treating 
patients will be explored in detail with this chapter. The main hypothesis is that 
targeting nuclear size with small compounds might lower the metastatic 
potential of that given cancer. Thus we tested the identified compounds in the 
high throughput screen in vitro in standard cell culture assays and in vivo for 
reduction of motility and reduction of the tumour size in xenografts models. 
The different compounds were chosen due to their tissue specificity identified 
during the screening process, namely oxyphenbutazone, paroxetine 
hydrochloride, parbendazole, piperlongumine and digitoxigenin (Table 11). 
 Oxyphendutazione is a nonsteroidal anti-inflammatory drug (NSAID) 
that has been shown to be a cancer chemopreventive agent in skin 
carcinogenesis  (Kapadia et al. 2010) and able to induce cytotoxicity in 
hepatocellular carcinoma model systems via inhibition of Wnt-b-catenin 
pathway (Saleem et al. 2017).  Paroxetine hydrochloride is an antidepressant 
of the selective serotonin reuptake inhibitor (SSRI) class and is used for 
treatment of different mental disorders as major depressive and obsessive-
compulsive disorders. It interacts with different enzymes of the cytochrome 
P450 complex (Sanchez, Reines, and Montgomery 2014), and it causes 
altered influx of calcium in astrocytes inducing mitochondrial-induced 
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apoptosis (Then et al. 2017). Parbendazole is a substitute 2-ammino derivative 
showing a broad spectrum anthelminthic activity. It has been proved as an 
extremely potent microtubule assembly inhibitor by direct binding to tubulin 
(Havercroft, Quinlan, and Gull 1981; Quinlan et al. 1981). Digitoxigenin is a 
cardenolide, the aglycone of digitoxin. Digitoxigenin has been shown to induce 
cytotoxic effects on non-small cell cancer cells, inhibiting the Na,K-ATPase 
activity and effective chemotherapeutic against metastatic uveal melanoma 
(Fagone et al. 2017; Schneider et al. 2018). Piperlongumine is a natural 
alkaloid produced by the plant of long pepper (Piper longum). This compound 
has been analysed in different studies due to its anticancer activity. The 
mechanism of action of piperlongumine is a strong interaction with the 
glutathione S-transferase Pi 1 that inactivates the enzyme generating a 
reduction of free glutathione and increase in ROS thus triggering apoptosis 
responses (Harshbarger et al. 2017; Raj et al. 2011). Piperlongumine has also 
been successfully used to treat breast cancer in xenograft models, showing 
reduction of the tumour volume and no metastasis (Bharadwaj et al. 2015; Raj 
















































4.2 Drugs altering nuclear size can impact cell motility   
 
Scratch wound healing assays are standard assays to establish effects 
on cell movement typically from protein knockdowns or chemical/drug 
treatments. A single monolayer of cells is typically mechanically disrupted by 
scratching with a teflon block though the cells can also be electrically wounded. 






































closure. If drug treatment is affecting the ability of cells to migrate, this will 
result in a longer time for wound closure. 
To be sure the measurement of wound closure is only dependent on the 
mobility of cells and not on cell division, cells are usually starved with 1% FBS 
containing medium and we did this 16 h before the scratch. Cells were treated 
with 6 different concentrations of the selected compounds in four replicates, 
immediately following the scratch and were recorded every 3 h for at least 48 
h. Analysis of the wound closure times against the controls revealed that only 
paroxetine hydrochloride had no effect on the migration of the cells at any of 
the concentrations tested. Oxyphenbutazone reduced the migration in a 
dose/concentration dependent manner until a concentration of 100 nM of the 
compound, where parabendazole has effects on the migration at higher 
concentrations (up to 1uM) but no statistical significant effects at the lower 
concentrations.  
(Fig 22A)  
Cell morphology was visibly altered in the oxyphenbutazone samples, 
with cells mostly rounded and marginally attached to the plate. This could 
mean a cytotoxic effect of the drug inducing apoptosis or necrosis in the 
sample. While this potentially increases its value as an anti-cancer compound, 
it makes it difficult to separate its effects specifically on cell migration. 
Nonetheless, such as effect seems logical as Oxypenbuatazone is known to 
actively depolymerize microtubules, which would inhibit cell migration. This 
also blocks mitosis and can be the explanation for a high number of cells with 
a rounded shape as opposed to the cells directly initiating apoptosis. To further 
elucidate the real effects of the drugs on cell proliferation and apoptosis 
additional tests for viability and cytotoxicity will be described in the following 
sections of this chapter. 
Piperlongumine and digitoxigenin were separately tested for wound 
healing assays in both the PC3 cells and the H1299 line. These wound healing 
assays showed a peculiar pattern with one drug having an effect on wound 
closure in one cell line and not the other and vice versa. Piperlongumine had 
a strong effect in the nuclear size screen at the two highest concentrations of 
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the serial dilutions used in the assay (10µM and 1µM) in PC3 and H1299 cells, 
but piperlongumine had no effects on nuclear size in H1299 until 36 hours of 
incubation. Digitoxigenin instead increased wound closure time in H1299 until 
a concentration of 100 nM, but had no effect in the PC3 cell line (Fig 22B-C).  
These results altogether indicate a high tissue specificity in targeting nuclear 















4.3 Drugs altering nuclear size can trigger apoptotic cascades   
 
One of the variables that is not always easy to distinguish in the wound 
healing assays is if the effects seen on the migration are directly due to 
reduction of motility or to induction of cell death impeding cell movement. This 
can be done using Annexin V labelling if the wound healing assay setup 
includes an immunofluorescence setup. However, in our case to avoid 
misinterpretation of the wound healing assays, I separately performed 
apoptosis and necrosis detection by FACS and viability assays. A good cancer 
therapy from our approach should be able to target motility and therefore the 
metastatic potential, but also not induce necrosis that triggers inflammation 
reactions. If the drug also induces apoptosis this would increase the efficacy 
of the treatment as it will act on the main tumour site, reducing the tumour size 
or growth, and if coupled with reduced migration and extravasation would 
prevent metastatic spread. Drugs could also reduce cell proliferation and not 
just induce apoptosis or necrosis, this would result as a not proliferative tumour 
without tumour growth. This effects will be tested later on in this chapter to gain 
a comprehensive view of the effects of each single drugs.     
The apoptosis or necrosis induction was detected with a standard 
Annexin V/Propidium Iodide staining before FACS detection. In the early 
stages of apoptosis one of the first events happening is the translocation of 
phosphatidylserine from the inner lipid layer of the plasma membrane to the 
outer. Annexin V has a high affinity for phosphatidylserine and cannot get 
through the lipid bilayer, which makes it a great marker to follow early stages 
of apoptosis as this outer plasma membrane staining appears. Propidium 
Iodide is also impermeable to the plasma membrane and so only gets into cells 
that have lost membrane integrity, thus allowing detection of cells in late stages 
of apoptosis and necrosis. The co-staining results in 4 different populations of 
cells, living healthy cells with no staining, early stage apoptotic cells positive 
only for Annexin V, late stage apoptotic cells positive for Annexin V and 
propidium iodide, and necrotic cells positive only for propidium iodide.  
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PC3 cells were incubated with drugs for 24 or 36 h, refreshing the 
medium every 24 h, and gating strategies for the analysis were decided for 
detection only in singlets and intact cells (Fig 23A). PC3 cells were chosen as 
the cell line to test as this was the first cell line screened and for which results 
were available first, and to keep consistency with the other analyses performed 
through this study.  
Analysis revealed that oxyphenbutazone has a strong effect on 
triggering apoptosis processes with 10% of cells being in an early stage and 
around 70% of cells in late stages of the apoptotic cascade. Parbendazole 
showed a lower ability to trigger the apoptotic process with around 20% of the 
cell population being in early and late stages of apoptosis. Paroxetine had no 
effect in inducing either apoptosis or necrosis, in line with no strong effect on 
migration in the wound healing assays. For this reason, this drug was removed 
from further analysis. Piperlongumine had a strong effect in inducing 
apoptosis, but not necrosis, to the same extent of oxyphenbutazone. Finally, 
digitoxigenin induced apoptosis and necrosis in this cell line with almost 70% 
of cells exhibiting necrosis or in in late stages of the apoptotic cascade (Fig 
23B). All together these apoptosis analyses show promising effects for 
oxyphenbutazone, parbendazole, piperlongumine and digitoxigenin to be 
further characterised and tested in more detailed assays to try and translate 














For viability analysis, a resazurine-based assay was performed. This 
assay allows quantification of live cells due to reduction of the resazurine to 
resorufine, a red and highly fluorescent compound, in healthy cells. The 
detection of either the absorbance or fluorescence of the coupled 
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resazurine/resorifine allows the determination of live cells numbers compared 
with controls. All cells were incubated for 24 h with serial dilution of the drugs 
to generate a curve dose-response. 
In line with the apoptosis/necrosis assay parbendazole and 
oxyphenbutazone reduce cell proliferation in all three cell lines at high 
concentration with low effects at the lower dilutions (Fig. 24A). Piperlongumine 
and digitoxigenin, on the contrary, have different effects on the three cell lines 
tested. Where piperlongumine has mainly the same IC50 in all three cell lines, 
digitoxigenin has much stronger effects on the prostate cancer PC3 cell line 
and less toxicity in the lung and colon cancer cell lines (Fig 24B). 
 
	









4.4 In vivo studies  
	
	 As most of the drugs in the PAD library are already approved by 
different government bodies for use in humans the drugs identified in my 
screens should have an easier translation to the clinic. To test if any of the 
compounds identified in the screen have a therapeutic effect in reducing the 
proliferation of tumours and spread of metastasis in a living organism, a 
xenograft mouse model was engaged. One of the main problems encountered 
in analysing the literature for the drugs taken into consideration in this chapter 
was to identify the IC50 for mice so that we could determine concentrations 
and dosage to be used for treatment in the xenograft models. 
Oxypehenbutazone and parbendazole have never been used in vivo for 
treatment of any xenograft models, therefore a control group with different 
concentrations and dosage was needed making these two drugs less attractive 
for initial in vivo experiments. Moreover, as these drugs have never been used 
and concentrations are not known, a negative result in xenograft models could 
miss a promising compound that simply needed a higher concentration used. 
The most promising drug that from literature and previous 
characterization could have effects on tumour growth is piperlongumine. This 
drug has been already been used in in vivo models and concentration and 
dosage have been tested with a strong effect in reducing tumour growth in 
different type of cancers, such as breast and bladder cancer. A prostate cancer 
xenograft mouse model was generated by injection of PC3 cells carrying a 
luciferase marker for detection of tumour size and spread in both flanks of male 
nude mice. The tumours were then allowed to grown and once tumours 
reached the size between 0.02 cm3 to 0.05 cm3, mice were randomized and 
treated daily through the weekdays either with a control solution of 10% DMSO 
or 15 mg/kg piperlongumine for three weeks. 
Tumours showed considerable growth the first week after injection, but 
were too soft for start the actual treatment. In the beginning of the second week 
there was a small reduction of the volume due to the matrigel dissolving. At 
the end of the second week tumours looked solid and ready for treatment (Fig 
25) Unfortunately, by the second week of treatment tumours in both the control 
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and the treatment group started declining due either apoptosis or necrosis, 
making reading of tumour size hard to perform and rendering the experiment 
a failure. However, differences in size were observed between the control and 
piperlogumine treated tumours with the piperlongumine treated smaller. This 
suggests that it is worth repeating the experiment, but in the next repeat of this 
xenograft model the tumour should allowed to grow for at least three weeks 
before starting the drug treatment and I will increase the amount of cells 
injected to account for possible cell death of this particular cell line. This repeat 
will unfortunately not be available until after submission of this thesis. 
   
	
Figure	25	Tumour	volume	and	growth	curve	for	DMSO	and	piperlongumine	xenograft	models.	Average	tumour	
volume	 and	 growth	 curve	 for	 control	 group	 treated	 with	 10%	 DMSO	 (5	 mice,	 10	 tumours)	 and	 15	 mg/kg	
piperlongumine	(5	mice,	10	tumours).		Tumours	were	monitored	by	calliper	measurements	at	the	beginning	and	
end	of	each	week	of	the	experiment.			
   
 
Pipelongumine has been shown to reduce tumour size in breast cancer 
and an inhibition of  STAT3, binding the pY-peptide ligand reducing the nuclear 
translocation, inhibition of ligand-induced and consecutive STAT3 
phosphorylation. This results in modulation of pre and anti-apoptotic genes 
leading to reduced tumour growth (Bharadwaj et al. 2015). To test if this can 
transpose into prostate cancer we performed ELISA assay for the total and 
phosphorylated STAT3. Results shown that there is a statistical significant 
reduction in pSTA3 between the control and the treated mice groups, but not 
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for the tSTAT3 (Fig 26). This suggests an activity of the compounds in possibly 
inducing apoptosis in prostate cancer tumours as well, arguing for a necessary 
repeat of the xenograft models to validate the data with a normal growing 







4.6 Chapter summary  
	
	 In this chapter I have shown that compounds identified in the screens 
of the preceding chapter have effects on different aspects of cell viability, 
motility and cytotoxicity, besides the ability of alter the karyoplasmic ratio. 
Taken together these results show that the targeting of nuclear size can lead 
to reduction of migration and therefore potentially less metastatic tumours. 
Note that effects on nuclear size alteration are tissue specific as well as the 
effects in migration, where a drug can have an effect on a particular cell line, - 
e.g. piperlongumine reducing cell motility in the PC3 cell line but not in the 
H1299 line. At the same time, drugs having effects on nuclear size might not 
have an effect on cell migration at all as per the compound paroxetine 
hydrochloride. This might be due to alterations of nuclear size that do not alter 
nucleoskeleton-cytoskeleton interactions or activation of a pathway that leads 
to nuclear size alteration without affecting motility function. In general, most of 
the drugs identified in the screen altering the karyoplasmic ratio or nuclear size 
and tested in this chapter have direct effects on cell migration. 
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Moreover, the compound treatments mostly resulted in the triggering of 
apoptotic cascades instead of inducing necrosis. This is extremely important 
in the development or repurposing of drugs as apoptosis cascades are 
preferred to necrosis as apoptosis does not induce inflammation processes in 
the tissue that are induced by necrosis and might have undesired effects on 
the patients. The induction of apoptosis is particularly interesting in light of 
some aggressive tumours where the detection of metastasis is already to an 
advanced state than in most cases is not curable. Compounds with tissue-
specific effects that combine inhibition of metastatic spread with killing of the 
tumour without also inducing inflammation are the theoretically most ideal for 
treating patients.    
In this chapter, I have performed a number of both cell culture and in situ 
assays to determine compound effects on cell migration, proliferation, viability 
and their effects on tumour growth. There are a number of additional assays 
that would be useful to further characterise these compounds, such 3D 
invasion assays that represent a great model for extravasation processes in 
vitro and give a better insight on the real migratory capacity and invasiveness 
potential of cancer cells and how this is altered by drug treatment.  
Using a pre-approved drug library in the screen will hopefully allow a faster 
translation into clinical usage, therefore the PAD library was chosen as the 
main library to perform the screen. Before translation into clinical usage of the 
identified drugs a xenograft mouse model is critical to assess potential benefits 
of drugs identified in the screen in reducing tumour growth and metastasis. 
Even though the drug used in our first xenograft model, piperlongumine, was 
known to reduce tumour growth in different other cancer types, a quick 
remission of the tumours in both treated and control mice during the treatment 
period made the result hard to interpret and a repeat of the xenograft model is 
required to prove the efficacy of piperlongumine in reducing tumour growth for 
prostate cancer. This will elucidate the real potential of nuclear size targeting 
as a new and effective targeting strategy to reduce metastatic potential of 
highly aggressive cancers and provide a tool for development of new drugs to 







5. Regulation of nuclear size driven by NETs and 
compounds: NET50 in prostate cancer 
 
5.1 Introduction  
 
The idea that adding compounds targeting nuclear size to other drugs 
in current chemotherapy regimens could be an effective treatment to reduce 
the metastatic potential of certain tumour types while reducing toxicity due to 
the tissue-specific effects has been the driving force behind this study and is 
strongly supported by the results of the previous two chapters. However, such 
treatments could be even more targeted and directed if the specific targets 
involved in the nuclear size changes to begin with were known. The NET 
screen identified several such candidate targets and suggests the hypothesis 
that some of the drugs may act on these NETs; however this hypothesis is as 
yet unproven. If nuclear size changes contribute to that increased metastatic 
potential and the tissue specificity of nuclear size changes in the different 
tumour types is driven by these tissue-specific NETs, then these NETs can be 
directly targeted in future screens for drug development. In this chapter I will 
investigate one of the proteins identified as a promising nuclear size regulator 
in the early and late stages of prostate cancer LNCaP and PC3 cells models, 
NET50. The chapter will explore in more detail the NET50 effect on nuclear 
size and then investigate both its potential interaction with a compound 
identified for correcting the nuclear size defect in the PC3 cancer model, 
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estradiol propionate, and the role of nuclear size changes in metastatic 
characteristics of the later stage prostate cancer.    
 
5.2 Prostate cancer progression 
 
 Prostate cancer is the most non-skin cancer in men in the Western 
world (Jemal et al. 2010). The progression through the disease is sustained by 
circulating androgens acting on the androgen receptor (AR). Levels of 
androgens are regulated through the hypothalamic-pituitary-adrenal-gonadal 
axis and at the diagnosis of the disease the androgen-deprivation therapy is 
used to reduce the androgens circulating to reduce the growth and 
sustainment of the tumour (Tsao et al. 2012). This results in most of the cases 
as temporary regression of the pathology in most patients, but the therapy or 
surgical castration tend to fail resulting in a new growth of the tumour. Several, 
despite castration, are the reasons allowing androgens to circulate and sustain 
the new growth of the tumour such as AR gene amplification or residual 
testosterone in the prostate microenvironment (Visakorpi et al. 1995). 
 
5.2.1 Current treatments for castration recurrent prostate cancer 
 
One of the current chemotherapy treatments for castration recurrent 
prostate cancer (CRPC) is estradiol (E2) which is believed to downregulate 
androgen production via a negative feedback control (Bosland 2005). Several 
studies on estradiol as an effective treatment for CRPC lead to different results 
and the literature is quite controversial on the topic; however, this is particularly 
interesting considering the dehydrogenase function of NET50/DHRS7 and the 
fact that estradiol was reported as one of its substrates (Skarka et al. 2014). 
Estradiol seems to be more effective than the currently used diethylstilbestrol 
in killing early and late stages of prostate cancer models in vitro, with the ability 
to activate different MAPs generating signalling cascades for the production of 
reactive oxygen species (ROS) or induction of caspase cleavage leading to 
either necrosis or apoptosis (Koong and Watson 2014). Estrogens, and in 
particular estradiol, have been shown to reduce CRPC growth in 
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orchiectomized mice xenograft models. The inhibition is related to the ability 
of estradiol to reduce intratumoural androgen levels and is not dependent on 
the presence or activation of the estrogen receptor (Montgomery et al. 2010). 
For these reasons estradiol has been proposed as a potential treatment for 
further investigation for targeting different aspects on steroidogenesis in 
prostate cancer.  
During the set-up of the parameters for the compounds high throughput 
screen, one of the compounds that shown alteration on the karyoplasmic ratio 
was and estradiol derivative, estradiol propionate. The set-up was performed 
with some plates form the Microsurce Spectrum library and estradiol 
propionate showed effects where other estradiol derivatives showed no 
alteration of the karyoplasmic ratio. Estradiol propionate is a direct estradiol 
derivative, bearing a carbonyl group instead of a single oxygen at C17b, and 
is a chemically synthetized compound not present in nature.  As it has been 
shown that NET50 has activity against steroid-like molecules and molecules 
carrying a carbonyl group (Štambergová et al. 2016) we postulated that the 
protein and the compound can potentially cooperate in regulating nuclear size 
 
	
5.3 Subcellular localization of NET50 
 
NET50, also known as DHRS7, retSDR4, and SDR34C1, is an orphan 
member of the short chain dehydrogenase/reductase (SDR) family. It was first 
isolated from retinal pigment epithelium cells (Haeseleer and Palczewski 
2000), but is expressed in a small subset of different tissues and most highly 
in prostate (Romanuik et al. 2010; Štambergová et al. 2016). Although DHRS7 
was separately identified as NET50 in a proteomic study of nuclear envelopes 
(Schirmer et al. 2003), it has also been reported as an ER-membrane bound 
protein (Skarka et al. 2014). Direct testing reveals it to be in both compartments 
(Fig 26). The topology of the protein is still debated as it was first postulated 
that the catalytic domain would face the lumen of the ER according to 
Štambergová et al., but as NET50 activity is not stimulated by ER-luminal 
H6PDH-mediated NADPH generation, the protein needs an alternative ER-
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luminal source of NADPH and a different orientation to gain access to the 
cofactor. Through the use of a digitonin permeabilization assay and based on 
similarity with other members of the SDR family a cytoplasmic orientation of 
the catalytic moiety has also been proposed by Araya and colleagues (Araya 
et al.).  
As poor titration of digitonin can lead to incorrect interpretations in 
digitonin permeabilization assays and the Schirmer lab has considerable 
expertise with this assay, I decided to directly test which of these studies is 
correct by myself determining NET50 topology with a digitonin assay. First, 
using the transmembrane span prediction TMHMM Server v. 2.0 identified a 
single region at the N-termini that is predicted as a hydrophobic helix to be 
inserted in the double lipid layer, in line with the other proteins of the SDR 
family. The assay allows to selectively permeabilize with digitonin the plasma 
membrane of cells previously transfected with the protein of interest tagged 
with a fluorescent protein. Antibodies against the fluorescent protein are used 
to detect the orientation for the protein of interest, if the fluorescent protein is 
exposed on the cytoplasmic side this will be detected by fluorescence signal 
as opposed to the protein not being accessible because presented in the 
nucleoplasmic side of the nucleus. Controls permeabilized with Triton X-100 
are used to asses that the antibody is effectively recognizing the fluorescent 
protein and known orientation proteins can be used as comparison. The 
digitonin assays revealed that the catalytic domain of the protein is facing the 
nucleoplasm/cytoplasm in line with experiments performed in Araya et al. 2017 
(Fig 27). As previous microscopy studies found NET50 co-localized with 
Nup153 and not with Nup358 (Malik, Zuleger, and Schirmer 2010), this places 
the protein at the inner nuclear membrane; therefore the catalytic domain is 
facing the nucleoplasm (Fig 20) and its dehydrogenase/reductase activity 









5.4 Function of NET50 
	
5.4.1 Screens for NET50 activity  
 
As the Schirmer lab is interested in understanding the functions of 
tissue-specific NETs and NET50 is very preferentially expressed in prostate 
they included it in several screens. The screens are based on the fact that 
ONM proteins likely affect the cytoskeleton and INM likely chromatin NET50 
has been tested in several screens performed in the lab and showed no great 
alteration of the cell cycle when overexpressed, although causing a slight delay 
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this was not considered relevant in the context of cell cycle alteration (Korfali 
et al. 2011). Alteration of cell cycle progression would explain the importance 
of this protein in cancer progression as one of the hallmark of cancer is 
unconditioned proliferation, allowing cells to master their own densities.  
Moreover, NET50 displays a localization at the nuclear envelope that is lamin 
A dependant as targeting of the protein is lost in lamA -/- cells (Malik, Korfali, 
et al. 2010) and no particular cytoskeleton defects when overexpressed in 
HT1080 cells (Malik, Korfali, et al. 2010). As the protein has multiple potential 
functions based on these studies, it is possible that the ER and NE populations 
have distinct functions and/or could have a similar function but on different 
substrates. 
 
5.4.2 Enzymatic activity of NET50 
 
Little is known about the reducing/dehydrogenase enzymatic role of 
NET50 in the cell, but biochemical studies on lipid-reconstituted purified 
NET50 protein revealed that it is a functional sterol dehydrogenase. Its 
substrate specificity in vitro highlighted an activity against normal cellular 
substrates such as all-trans retinal and steroids such as A-dione and cortisone. 
The protein seems to have activity also against non-endogenous substrates 
bearing a carbonyl group such as 1,2- naphtoquinone, 9,10- phenanthren 
equinone, benzoquinone, and nitrosamine 4- (methyl- nitrosamino)- 1- (3- 
pyridy l)- 1- butanone (Skarka et al. 2014; Štambergová et al. 2016). All these 
activity measures were inferred by indirect chromatographic analysis of the co-
factor NADPH:NADP+ ratio after incubation of the protein with the different 
substrates. Other evidence suggests NET50 to be involved in the inactivation 
of 5α-dihydrotestosterone, implying a role for the modulation of the AR 
transcriptional activity and therefore the importance of the protein as an anti-
cancer player (Araya et al. 2017). Most of prostate cancer starts with an 
androgen-dependant growth, but as the cancer progresses cells are able to 
activate androgen receptor elements and response even in presence of a 
blockade of androgens. NET50, with a role in modulating and inactivate a 
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precursor of testosterone might be a crucial protein in control of prostate 
cancer progression.   
 
5.4 NET50 as biomarker for prostate cancer  
 
Several recent studies have shown a reduction in the expression of 
NET50 in prostate cancer (Romanuik et al. 2010; Seibert et al. 2015), leading 
to the hypothesis that the downregulation of NET50/DHRS7 can be used as 
an effective biomarker for prostate cancer prognosis.  
Staining normal prostate tissues and prostate cancer tissues with a 
polyclonal DHRS7 antibody highlighted a progressive loss of the protein during 
cancer progression with the lowest staining associated with the specimens 
with worse Gleason level scores (Seibert et al. 2015). Gleason level is the 
score system for prostate cancer that associates a grade depending on the 
appearance of cancer tissues under the microscope that includes both nuclear 
shape and size changes. For prostate cancer prognosis, the specimen is first 
associated with one of five progressively worse microscopic patterns to assign 
the Gleason score. Primary, secondary and tertiary grades, depending on the 
percentage of the pattern in the specimen, are then decided and the final grade 
results as the sum of the pattern score of the primary grade and the highest 
pattern between secondary and tertiary allowing a final grade score from 2 to 
10 with 2 representing the lowest score and most well differentiated tumours 
oppose to 10 associated with least differentiated tumours  (Humphrey 2004). 
In addition to demonstrating the correlation between loss of NET50 and cancer 
severity, the authors of this study knocked down NET50 in earlier stage 
prostate cancer cell lines that still expressed it resulting in increased 
proliferation, invasiveness and less adhesion to the substrate (Seibert et al. 
2015). This was assessed with a proliferation assay and Ki67 staining for 
proliferating cells, measuring the growth curve and intensity of Ki67 staining of 
siRNA depleted cells phenocoping the increased and uncontrolled proliferation 
of cancer cells. Trans-well migration and fibronectin adhesion assays were 
used for invasiveness and adhesion, to test motility and ability of cancer cells 
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to extravase from the primary tumour and spread in different sites, another 
important feature of more metastatic tumour cells (Seibert et al. 2015). All 
together these results suggested an important role of this protein in prostate 
cancer progression for which loss correlates with more aggressive cancer 
cells.  Studies on the transcriptome of LNCaP cell line, the model cell line for 
early stages of prostate cancer where NET50 is still expressed, suggested a 
key role for NET50 in leading to the reactivation of the androgen receptor (AR). 
This is because NET50, likely through its dehydrogenase activity, sustains de 
novo androgen synthesis and/or metabolism in castration recurrent prostate 
cancer (CRPC), flagging the protein as an important anti-cancer protein in this 
type of cancer (Romanuik et al. 2010). Thus, reactivating NET50 in late stage 
prostate cancer might help the patient through its function with androgen. We 
wondered if its function in nuclear size regulation might also be relevant. 
5.7	NET50	can	regulate	nuclear	size	in	prostate	cancer	
 
Although NET50 reduced the normal nuclear size of HeLa nuclei when 
overexpressed in our screen, we had not tested for volume changes or if 
knockdown also affected nuclear size. We specifically confirmed these results 
in HT1080 cells both in 2D, analysing the mid cross sectional area of several 
nuclei, and in 3D with nuclear volume reconstructions of z-stack images from 
the nuclei of NET50 overexpressing cells.  
To determine if NET50 nuclear size alteration is maintained in a prostate 
cancer model I used two different prostate cancer cell lines representing 
different stages of cancer progression, LNCaP and PC3. The LNCaP prostate 
cancer cell line, isolated from lymph node metastasis, resembles the early 
stages of prostate cancer development and expresses the androgen receptor 
so is therefore androgen sensitive. On the other hand, the PC3 prostate cancer 
cell line, isolated from lumbar metastasis, resembles a late stage of prostate 
cancer, is androgen insensitive due to the lack of expression of the androgen 
receptor, and has a higher metastatic potential. This cell line being a highly 
metastatic cell line established form a grade IV tumour, presents 
characteristics morphological features of a poorly differentiate tumour with 
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different sub-phenotypes, comprising epithelial like and neuroendocrine cells 
(Kaighn et al. 1979).  
Immunofluorescence and Western blotting with a monoclonal antibody 
targeting the C-terminal region of NET50 were used to assess the presence of 
the protein in the LNCaP and PC3 cell lines. As expected the cell line 
resembling the early stages of prostate cancer progression (LNCaP) shows 
the presence of the protein at a NE subcellular localization where the cell line 
resembling the late stage of prostate progression (PC3) shows downregulation 
of protein expression and no localization at the NE or in the ER (Fig 29A-B). 
Though no degradation products were observed in the PC3 cells with this 
antibody it is unclear whether the nucleoplasmic staining is background for the 
antibody in the absence of antigen, if there is a cleavage product that is still 
recognised by the antibody, or if there is cross reactivity of the antibody with 
other close members of the protein family. 
 
	









To investigate the role of NET50 in nuclear size regulation, transient 
overexpression of a mRFP fluorescently labelled NET50 was performed and 
this resulted in reduction of the nuclear volume of ~60% for both cell lines with 
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statistical significance for both samples. Roughly 100 PC3 nuclei for each 
condition were analysed to take into account the different sub-phenotypes that 
the cell line develops in culture. By contrast, knocking down NET50 via 
transient transfection of a pool of siRNAs against its mRNA transcript resulted 
in a statistically significant increase of the nuclear volume in the LNCaP cell 
line. (Fig 30A-B) Cells were analysed if a clear nuclear envelope ring of 
fluorescence was detected for the overexpression samples, or if completely 





only.	Western	 blot	 showing	 the	 effective	 knockdown	 of	 the	 protein	 in	 the	 LNCaP	 cell	 line.	 B.	 Nuclear	 volume	
reconstruction	 for	 overexpression	 of	 the	 protein	 shows	 a	 decrease	 for	 the	 control	 cell	 line	 HT1080	 and	 both	
prostate	cancer	cell	 lines	LNCaP	and	PC3.	NET50	knockdown	in	the	LNCaP	cell	 line	results	in	an	increase	of	the	





5.8 Estradiol propionate reduces nuclear volume   
 
Since estradiol has been used as an effective remedy for CRPC, and 
because estradiol propionate was one of the hit compounds in the pre-screen 
optimization with the Spectrum Library for compounds altering nuclear size, 
we were interested in testing the effects of this compound in a prostate cancer 
system. Both cell lines were treated with 2 different concentrations (10µM and 
3µM) of the compound for the whole duration of the transfection protocol and 
thereafter, replacing the medium with freshly added compound every 24 h. 
Compound treatment resulted in a decrease of nuclear volume of ~70% for the 
PC3 cell line where the protein is not expressed and no statistical significant 
alteration in the LNCaP cells, where the protein is still expressed (Fig 31A).   
To establish if it is the presence or the catalytic activity of the protein that is 
required to disrupt the nuclear volume reduction by the compound, NET50 was 
ectopically overexpressed with transient transfection in the PC3 cell line where 
the protein is not normally expressed and knocked down in the LNCaP cell line 
where it is normally expressed. Treating these cells with two different 
concentrations of estradiol propionate resulted in the reduction of the nuclear 
volume only where NET50 is not expressed (Fig 31B). 
This suggested either a mechanism of suicide inhibition by the estradiol 
propionate on NET50, that binding to the catalytical pocket neutralizes the 
action on nuclear size regulation for both the protein and the compound, or 
both NET50 and estradiol propionate are part of the same pathway that lead, 











5.9 NET50 predicted catalytic site mutations block its nuclear size 
effects  
	
To determine if the catalytic activity of NET50 is required to direct 
nuclear volume alterations, site directed mutagenesis to generate point 
mutations of the protein was performed. As crystal structures of the protein 
have not yet been solved, the protein sequence was run on the Phyre 2 server 
to identify similar domains in an already crystalized member of the superfamily. 
One of the most similar structures predicted by the server with a 100.0% 
confidence is the human 17-beta-hydroxysteroid-dehydrogenase type 1 (PDB 
1FDV), a closely related member of the SDR family (Fig 32A). Following a 
bioinformatics study on the whole SDR family by Bray and colleagues (Bray, 
Marsden, and Oppermann 2009) the key residue coordinating the cofactor 
NADP was identified as arginine R38 in 17-beta-hydroxysteroid-
dehydrogenase type 1 and the predicted residue for NET50 is arginine R82. 
By aligning the sequences of the two proteins with proper numeration, arginine 
R82 was confirmed as a potential residue to mutate and the mRFP-NET50-
R82E mutant was designed and generated (Fig 32B). 
Transient overexpression of the mutant construct using the PC3 cell line 
as a NET50 null background resulted in a statistically significant increment of 
the nuclear volume, phenocopying the increment of nuclear volume in knock 
down of the protein in the LNCaP cell line (Fig 32C). This suggested a minimal 
residual protein is still expressed in PC3 cell line, despite not being able to 
detect this on a western blot, with a dominant negative inhibition of NET50.  
Cells were then treated with 2 concentrations of estradiol propionate in the 
presence of the mutant protein leading to a volume reduction as if the protein 
was not expressed at all, suggesting a catalytically dead mutant as 
fluorescence was detected but no reduction of the nuclear volume occurred as 




Figure	 31	 NET50	 enzymatically	 dead	 mutation	 prevents	 its	 nuclear	 size	 effects	 and	 allows	 the	 estradiol	












5.10 Chapter summary  
 
In this chapter a new NET, NET50/DHRS7, has been shown to have an 
effect on nuclear size regulation in a prostate cancer in vitro cell system. The 
observations of loss of the protein expression in cancer progression as shown 
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in other studies (Romanuik et al. 2010; Seibert et al. 2015) and the fact that 
increased nuclear size is a diagnostic feature for the later stages and higher 
grades of prostate cancer are now linked through our data showing that NET50 
loss causes an increase in nuclear size. It is unclear what are the factors that 
lead to the downregulation of the protein during the later stages of prostate 
cancer, but these correlations raise the possibility that restoring normal nuclear 
size might reduce the cancer severity. One hypothesis is that regulation of 
nuclear size by the protein can involve the catalytic activity of the protein. 
Given the similarity with different members of the SDR family NET50 could be 
involved in the regulation of steroidogenesis, with steroids being fundamental 
molecules for the maintenance of healthy prostate tissues and regulators of 
uncontrolled proliferation of cancer cells. For example, NET50 could process 
small molecules into active compounds that can directly influence the 
transcription of different genes involved in the maintenance of normal nuclear 
size. Another mechanism by which the protein could act in nuclear size 
regulation is by association with other proteins at the NE that are able to anchor 
and repress oncogenes that, in absence of the protein, get released from the 
NE and cause the nuclear size alteration and progression of prostate cancer. 
As NET50 has not been linked with genome repositioning and organization 
activity in the screens performed in the Schirmer lab so far, the only possible 
explanation for a possible involvement of the protein in influencing genome 
organization is if it is able to form a complex with other NETs with genome 
organisation properties.   Considered together these results are consistent with 
NET50 being a key regulator of nuclear size, at least in prostate cancer 
development, and that it might be used as biomarker for earlier and better 
identification of early stages of this pathology, as suggested by Seibert and 
colleagues, or as an effective target for new anticancer drug target. 
Further investigation into whether alteration of the nuclear size is 
dependent of the enzymatic activity of the protein or dependent on the 
association of the protein with other partners to from a complex is required. 
Interestingly, the effects on nuclear size alteration from the loss of the protein 
are reversed if cells are treated with estradiol propionate, having the same 
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nuclear size reduction effect. In the other direction, overexpression of NET50 
to reduce nuclear size is not augmented when also treating the cells with 
estradiol propionate. This might be explained by a catalytic alteration of 
estradiol propionate by NET50, resulting in a non-active metabolite rendered 
unable to affect nuclear size. Estradiol propionate, being a hormone, has the 
characteristic steroid structure as A-Dione and testosterone for which activity 
has been shown for NET50 and other members of the SDR protein family. 
Moreover, estradiol propionate carries a carbonyl group, a key chemical group 
shown to be a substrate of NET50 enzymatic activity (Štambergová et al. 
2016).  Another explanation for the lack of an additional effect on nuclear size 
if both protein and compound are present is suicidal inhibition of the protein by 
the compound. Influence on the nuclear size regulation is most likely related 
to the catalytic activity of the protein, as the catalytically dead mutant (R82E) 








6. Discussion  
 
6.1 Nuclear size in cancer 
	
 
Nuclear size and shape alterations are one of the most evident morphologic 
aberrations visible in cancer tissues and have been used for decades to stage 
and grade cancer in an effective and precise way (Cibas and Ducatman 2014). 
These alterations could be a direct cause of the worsening patient outcomes 
or may be an indirect consequence of other factors that affect outcomes. For 
example, upregulation of chromatin compacting proteins due to aberrant gene 
expression can lead to a state of compaction of the genome resulting in the 
shrinking of the nucleus, or alteration of lipid synthesising enzymes at the NE 
might lead to the insertion of excessive amounts of lipids in the NE membranes 
resulting in an enlargement of the nuclear size. In this study, we investigate 
the regulation of nuclear size as a new potential approach to effectively target 
tumour progression and lower the metastatic potential of highly aggressive 
cancers.  
There are certainly many ways that a nuclear size change itself or 
associated changes in NE-chromatin or NE-cytoplasmic filament connections 
can provide direct advantages to cancer cells. These range from aspects of 
metastasis such as increased cell migration and an enhanced ability to 
squeeze through cell junctions in invading other tissues to an increased 
proliferative capacity and altered gene expression. Therefore, understanding 
the basic mechanisms or the factors that can influence these morphological 
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alterations is a first step to specific targeted approaches for treatments based 
on nuclear size changes. That these changes are tissue-specific may allow for 
such targeted approaches to focus toxicity in the particular tissue and so not 
only allow for chemotherapeutic treatments resulting in better patient 
outcomes, but also reduce the side effects of chemotherapy and improve 
quality of life during these stages of the cancer. The current focus of the cancer 
community is to target central pathways and signal cascades, especially 
kinases, in cancer treatments, arguing that the metastatic process is just a 
secondary effect and cannot be properly controlled or targeted effectively 
(Fidler and Kripke 2015; Steeg and Theodorescu 2008). There are currently 
many studies being carried out trying to target several kinases in the hope to 
identify or repurpose drugs to be effective in treating both primary tumours and 
metastasis (Collins et al. 2019; Miao et al. 2019). 
Here we propose a more phenotypic approach, targeting one of the more 
evident morphological alterations, nuclear size, detected in cancer progression 
in several tumour types.      
 
 
6.2 NETs involved in nuclear size regulation are tissue specific 
	
 
The hypothesis that different phenotypes for nuclear size and shape 
detected in different type of cancers could be driven by tissue-specific nuclear 
membrane proteins has been central for this study. Researchers focused on 
nuclear size regulation until now have focused on trying to identify a communal 
factor or factors that could explain the nuclear size alteration in all the different 
cancer types. This has yielded deep understanding of factors that can 
influence or regulate nuclear size, such as lamins that have been implicated in 
direct nuclear size regulation in a concentration dependent manner (Jevtić et 
al. 2015) or protein like Nesprins directly involved in nuclear size regulation 
(Luke et al. 2008).  Despite the effort and research on these factors no clear 
answer has been identified to explain the differences of nuclear size alteration 
detected in the different cancer types. We here shift the focus, arguing that a 
	 121	
more tissue specific view could be the answer to identify potential regulators 
of nuclear size. It makes sense that nuclear membrane proteins would be 
involved in nuclear size regulation as control of nuclear size requires the 
regulated growth of the nuclear membrane and production of its component 
proteins. These in turn have many connections to chromatin and the 
cytoskeleton and so maintaining nuclear mechanical characteristics through 
the cell cycle requires that this process be tightly regulated so that the balance 
of connections to both chromatin and the cytoskeleton is maintained. As recent 
years have found that the NE is in fact a highly-specialized organelle rich with 
tissue-specific proteins (Schirmer et al. 2003), it further follows that the tissue-
specificity in the characteristic degree and directionality of nuclear size 
changes would likely be directed by tissue-specific NETs. In this study, several 
NETs were screened for their ability to potentially regulate nuclear size 
variation in different cancer models.  
  As the results suggested there is a tissue specificity in how these 
proteins influence the nuclear size, with some proteins (e.g. Emerin or NET39) 
having different directionality in altering the nuclear size depending on the 
tissue in which they are expressed. This result even more interesting when 
considered in light of the gene copy number alterations of these NETs in 
cancer patients. Some NETs that increase nuclear size when overexpressed 
and when knocked down yield decreased nuclear size were hemi-amplified in 
a type of cancer in which the increased nuclear size correlates with worse 
grade and hemi-deleted in cancer where decreased nuclear size correlates 
with a more severe and aggressive cancer. This suggest that these NETs 
might have the ability to regulate the nuclear size changes during cancer 
progression.  
There are many mechanisms by which changes in nuclear size may 
lead to even more severe tumour progression. An abnormal increase of 
nuclear size can disrupt important connections between the chromatin and the 
NE, thus releasing large portions of the genome into the nucleoplasm. This 
could cause genes in these regions that are normally kept tightly shut off in the 
repressive environment characteristic of the NE to become active. If such 
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genes included oncogenes or cell cycle proteins that increase proliferation, this 
would result in a more metastatic tumour. Activation of kinases could have 
many pleiotropic effects on cells ranging from affecting nuclear import of critical 
transcription factors to phosphorylation of structural elements such lamins 
leading of disassembly of the main structural element of the nucleus (Lee et 
al. 2007). Kinases are also part of complex cascade responses, alterations of 
early responding proteins can easily result in activation or repression of several 
final actuators. These final actuators could be genes and proteins that allows 
advantages to the tumour cells such us unconditioned proliferation or better 
cell motility favouring the spread of the tumour in secondary sites. For 
example, the nuclear envelope is linked to the Wnt pathway through different 
proteins (Jamieson, Sharma, and Henderson 2014; Luke et al. 2008b), 
therefore the loss or overexpression of these proteins in cancer can lead to 
incorrect activation or inhibition of oncogenes that could potentially result in 
altered nuclear size. Abnormal nuclear size alteration might also effect 
cytoskeletal connections via disruption of connection between the nucleus and 
plasma membrane, potentially resulting in alteration of cell migration giving 
cancer cells an advantage in the process of metastatic spread. Cytoskeletal 
connections can also be altered by gene expression changes that alter the 
amount of key proteins involved in nucleoskeletal-cytoskeletal connections. 
For example, a reduction of expression of proteins of the LINC complex due 
to repression induced by reduction of the nuclear size, and therefore more 
compact and silenced chromatin, would lead to less proteins available at the 
NE for proper connections with intermediate filaments and microtubules.  
My screen focused on the overexpression of proteins mimicking an 
upregulation of that particular protein during cancer progression. This would 
have been better if we had also performed the screen knocking down the pool 
of proteins. This would both have allowed determination if overexpression and 
knockdown of these NETs have opposing effects and this analysis may also 
give an even deeper understanding in the contribution of NETs in nuclear size 
regulation. We did not do the knockdown in the first place for all NETs 
screened because of difficulties in removing NETs that appear to generally 
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have a longer half-life than soluble proteins. However, now that CRISPR/Cas9 
technologies are well established and can obtain knockdown of proteins in a 
reasonable amount of time, performing the screen to knockout NETs at the NE 
might help identify more proteins involved in nuclear size regulation and thus 
provide more candidates that will be worth considering as targets for cancer 
therapies. Another reason the knockdowns were not undertaken in the first 
analysis is that several of the NETs have protein pools in both the ER and in 
the NE. In these cases for the knockdown it would be difficult to determine 
whether the effects were more direct due to loss of the NE pool or indirect from 
a separate function of the ER pool. With further investigations of NETs in 
general it might be possible to identify splice differences or post-translational 
modifications that differentially direct the protein to the ER or NE. With this 
information, CRISPR/Cas9 could be used to replace the wild-type gene for 
example with one that has a phosphomimic mutation that keeps the entire pool 
in the NE or a phosphonull mutation that keeps it all in the ER. This would 
allow a better determination of roles and mechanisms behind the nuclear size 
changes for particular NETs. 
The NET screen was only performed with 50 NETs, but there are 
several hundred in each tissue tested and because the majority are tissue 
specific the total number is closer to 1,000. Thus if further screening could be 
done it would likely identify many additional nuclear size factors if this larger 
set of proteins could be screened. 
There are also some caveats to the methodology of the screening. High 
throughput screening has the major benefit that it allows the analysis of a large 
amount of variables once parameters and conditions are set up, but it can 
harbour different types of false positives. In particular, for this type of screen 
one of the more problematic variables is that high transfection efficiency is 
more difficult to achieve in 96 well format than in standard tissue culture plates 
while the cytotoxicity is often higher. This is likely due to several factors 
including: 1) the fact that cells do not adhere and spread as well on optical 
plates as standard tissue culture coated plates and it is not possible to coat 
the glass with most substrates that would enhance adherence and spreading 
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without compromising the optical qualities for screening, 2) capillary action in 
the small wells prevents an even distribution of cells, 3) the ratio of volume to 
surface area is greatly perturbed in small wells, 4) difficulties in changing the 
medium, as cells tend to adhere less, making frequent media changes not a 
valid option. These changes could result in erroneous measurements of the 
nuclear area due to a low number of transfected cells or low expressing cells. 
Moreover, cells might undergo apoptosis during the transfection procedure for 
several reasons, such as high cytotoxicity of the transfection reagent or 
impurity in the DNA used for the transfection, and this can result in erroneous 
nuclear size readout. To remove false positives in the screening process due 
to these issues, positive hits should be furtherer investigated with a more 
detailed approach as 3D volume reconstructions to confirm the accuracy of 
readings for nuclear size effects. We did this for NET50 because of its 
preferential expression in prostate and our focus on prostate cancer, but there 
were many other potentially interesting candidate NETs that should be further 
evaluated with 3D analysis.    
 
 
6.3 Compounds targeting nuclear size show tissue specificity  
	
 
 Similar to the tissue specificity observed for NETs, the drugs affecting 
nuclear size also were tissue-specific in their effects. This suggests that they 
can be more effective against one particular type of cancer by specifically 
targeting that tissue type and accordingly have less toxic side effects on 
patients by not doing systemic damage. Targeting nuclear size alterations in a 
tissue specific manner can be a valuable direction for the discovery or 
repurposing of drugs. Screening for drugs altering this feature in different 
cancer cell lines revealed that only a subset of drugs is shared between all the 
cell lines, where most of the hits are indeed cell line restricted and therefore 
cancer type specific.  
 Comparing karyoplasmic ratio and nuclear size as the method of 
analysis for the identification of new compounds revealed that the 
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karyoplasmic ratio harboured less hits. In the early stages of use of nuclear 
changes in cancer diagnosis the karyoplasmic ratio was used, but this was 
quickly replaced with simply nuclear size because it is much easier to stain just 
for the nucleus for quantification of size changes (Fischer 2014; Taira et al. 
2012b; Veta et al. 2012). Thus, it is not even clear for all cancer types using 
nuclear size changes diagnostically whether the karyoplasmic ratio also 
changes. This is nonetheless an important distinction because a cell with a 
nuclear size increase could also have the cytoplasm increase so that the 
karyoplasmic ratio is unchanged. Such a cancer type would likely be different 
in cause than one in which the sensing mechanism that links the nuclear size 
increases to cell size increases breaks down. Correspondingly, it will be 
important to determine clearly for all these cancer types if the nuclear size 
increases used for grading involve a disruption of the karyoplasmic ratio as if 
the karyoplasmic ratio is disrupted a smaller group of compounds can be 
focused on. It is noteworthy that another benefit of the high-throughput Opera 
screening platform is that with multiple parameters determined the analysis 
can be adapted in many ways and just as treatments yielding a change in the 
karyoplasmic ratio can be determined so can treatments that exhibit an 
equivalent change in both nuclear and cytoplasmic volume.  
 As mentioned for the NETs screen, high throughput screening might 
harbour erroneous hits that need to be verified with more focused approaches. 
For the drug screen one of the most problematic aspects is cytotoxicity of the 
drugs that might trigger apoptotic or necrotic responses that would result in 
false-positive hits as both nuclear size and karyoplasmic ratio will be altered in 
necrotic and apoptotic cells. Adding a different apoptotic or necrotic marker 
would facilitate the removal of potential compounds highly toxic for the cells. 
The compounds inducing apoptosis would be still a valuable hit that can be 
used in follow up analysis due to their potential in being useful to reduce 
tumour growth in vivo and highly toxic compounds may be used for shorter 
treatment times, which is why the screen was performed at both 6 and 36 h.   
The screen identified several classes of compounds as strong hits in all 
the cell lines and with different directionality for the nuclear size alteration such 
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as 5-HT serotonin uptake and cyclo-oxygenase inhibitors or Na+/K+ ATPase 
and COX inhibitors. Microtubule depolymerising agents were identified both as 
increasing and decreasing the nuclear size in different cell lines, this might be 
a case of an erroneous read out as cells will be blocked in mitosis due to the 
lack of proper spindle formation leading to cell death, but represent a good 
example of how compounds leading to apoptosis or cell death can interfere 
with the assay readout. At the same time, this is a good example of how the 
assay identified compounds that can be used to target tumours based on a 
range of criteria with the high-throughput data collection and supporting these 
hits several studies have shown the efficacy of the microtubule depolymerizing 
agents in being effective against cancer cells (Dumontet and Jordan 2010; 
Jordan and Wilson 1998).  
To improve further the screen, it would be interesting to follow different 
variables and sizing of different organelles within the cell. This was the original 
idea of the compound screen in which we intended to monitor four different 
organelles at the same time through fluorescent proteins fused to signal 
sequences, namely the nucleus, the nucleoli, the ER and mitochondria. 
Screening for different parameters would have generated a more 
comprehensive view of mechanism of action of different compounds in scaling 
different compartments of the cell and allowed for the identification of drugs 
with different clinical or industrial benefits. For example, identification of 
compounds inducing increase size in ER could be benefit for industrial purpose 
in mammalian protein production. The actuation of this type of screening was 
not successful due to several problems with cloning and the impossibility to 
obtain a final working lentiviral vector, but with recent improvements and 
development of plasmid DNA synthesis it would be a viable option for the 
generation of this vector and stable cell lines.  
Finally, as the screen results in a more manageable number of 
compounds compared to the initial numbers of the library, it would be useful to 
characterise deeper the effects of the compounds affecting nuclear size with 
volume 3D reconstructions to fully understand the size, and possibly shape, 
alteration effects.  
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6.4 Protein and compounds influencing nuclear size can interact 
	
 
Although the NET and compound screens were engaged 
independently, we expected that some compounds would be specifically 
targeting the NETs that alter nuclear size for their effects. Accordingly, we had 
planned a third screen involving biochemical and biophysical screening 
techniques on recombinant produced proteins. These comprise assays such 
as plate based size exclusion chromatography that is a miniaturized screening 
method for homogeneous in-solution affinity selection. Target proteins are first 
incubated with compound pools and protein-compound complexes are 
separated by size exclusion chromatography. The eluted fractions are then 
analysed by Liquid Chromatography-Mass Spectrometry (LC-MS/MS) for the 
identification of compounds binding to the target. Another approach that could 
be used to identify compounds interacting with recombinant proteins is the on 
beads CONA screening where fluorescent labelled proteins are incubated with 
an on beads library and interaction between compounds and protein can be 
detected by a fluorescent ring around a bead. The positive beads can be 
picked and analysed by mass spectrometry to identify the interacting 
compound.  
 Even without getting the CONA assay off the ground, we nonetheless 
did find at least one compound that acts on a NET that regulates nuclear size 
changes. In this case, NET50 and the compound estardiol propionate 
cooperated in altering nuclear size. NET50 had an effect in reducing nuclear 
size when overexpressed in prostate cancer models, suggesting an active 
involvement of this protein, progressively lost during cancer progression, in 
maintaining a normal nuclear size in healthy tissues. Mutation of the 
coordinating residue for the cofactor of the protein results in loss of decrease 
effect on nuclear volume arguing for an involvement of the catalytic function of 
the protein in the process of nuclear size regulation.  
As per the compound side of the nuclear size regulation, estradiol 
propionate had an effect of nuclear size reduction in a concentration 
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dependant manner. This decrease in nuclear size is lost or masked when 
NET50 is expressed in the cell. There are several hypotheses that could 
explain the mutual exclusive nuclear size effect, such as process of suicide 
inhibition in which the compound interacts with the catalytic pocket of the 
protein, thus blocking the normal catalytic function of the protein. This is 
supported by the activity of close members of the SDR family, active against 
steroid like substrates (Lidén and Eriksson 2006; Marchais-Oberwinkler et al. 
2011), and as estradiol propionate is not a circulating hormone, derivate from 
a potential natural substrate of the protein, might have the correct conformation 
and charge to be accommodate in the catalytic pocket, but impeding the 
normal catalytical mechanism of NET50. Estradiol derivatives have been 
shown to effectively inhibit the 17b-Hydroxysteroid dehydrogenase, a close 
member of the SDR family to NET50, in cell-free assay by blocking the 
substrate pocket (Bérubé and Poirier 2009; Qiu et al. 2002). Another 
explanation for the absence of nuclear size effects when both protein and 
compound are present at the same time is for NET50 to actually use estradiol 
propionate as a substrate, generating a new compound that can not longer 
induce nuclear volume reduction in the cell. This can be explained with the 
identification of activity of the protein against carbonyl groups (Štambergová 
et al. 2016), for which estradiol propionate is an example, flagging the 
compound as potential substrate that gets modified losing the nuclear size 
reduction when the protein is still expressed in the cell.   
Several and deeper investigations of the relationship between the 
estradiol propionate and NET50 are required to fully elucidate the mechanisms 
of nuclear size regulation. But this work provides an example of how selectively 
targeting a single protein involved in nuclear size, for which loss of expression 
during cancer progression is associated with more severe tumours, could 







6.5 Targeting nuclear size might reduce metastasis and tumour growth 
	
 
Targeting nuclear size, either via targeting a protein or through an 
independent effect of a compound, might result in reduction of the metastatic 
potential of tumours. This was the case for most of the compounds tested 
where in addition to their action in altering nuclear size they induced apoptosis 
and inhibit cell migration in wound healing assays. These effects could be the 
result of different functions targeted by the compounds as, for example, 
microtubule de-polymerising agents could alter the cytoskeleton connections 
resulting in less migration as already proven as effective anti cancer therapy 
(Dumontet and Jordan 2010; Jordan and Wilson 1998).  
Another potential mechanism is that nuclear size changes could either 
influence chromatin compaction leading to a smaller or harder nucleus and 
likewise increase in nuclear size can lead to less chromatin contacts, allowing 
a more malleable nucleus. In the former case the smaller nucleus might be 
able to migrate easier by fitting through tight junctions, but the same time could 
derive from the increased nuclear size in the latter case because a more 
malleable nucleus could deform to squeeze through the tight junctions. Drugs 
that tend to restore the normal nuclear size have been the focus of this study, 
but even drugs that further increased or decreased nuclear size could lead to 
an imbalance in connections between the nucleus and the cytoskeleton so that 
the cell migration capacity might be mitigated. In addition to directly affecting 
migration, these changes in chromatin contacts could results in deregulation 
of cancer gene expression patterns, as for example affecting the Wnt or Tgfb 
pathways as the nuclear envelope is directly linked to the regulation of these 
pathways (Jamieson et al. 2014; Markiewicz et al. 2006; Neumann et al. 2010). 
Thus, the compounds affecting nuclear size in both directions could potentially 
actually have beneficial treatment effects for reducing metastasis. 
The mouse model presented in this study had problems with the control 
tumours not growing and so have not been useful thus far to gain insights in 
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vivo on how compounds affect nuclear size targeting and reduction of tumour 
growth and metastatic spread. However, previous literature has shown 
successful tumour growth reduction in other cancer types for piperlongumine 
(Bharadwaj et al. 2015; Raj et al. 2015), suggesting a possible efficacy of the 
nuclear size targeting strategy. The xenograft model needs to be performed 
again allowing the tumour to develop properly before starting with drug 
treatment, making sure the effects of the drug are not masked by the 
progressive degeneration of the tumour in both control and treated groups. 
This will allow to establish if targeting nuclear size can be effective against 
tumour growth and can be further translate into clinic for effective treatment of 
patients. 
Once the effects of identified compounds are confirmed in vivo in 
xenograft models, would be interesting translate them in a more clinical 
perspective. Many questions arise when administering new drugs to patients, 
for example if the compounds identified can be just add to pre-existing 
chemotherapeutic regiments or the drug can be used to substitute an existing 
one reducing the side effects. In theory, as the aim of this project has been to 
reduce the metastatic potential of highly aggressive tumours by targeting the 
nuclear size, adding the identified compounds could result in a containment of 
the tumour within its primary site, while the already in use chemotherapeutic 
treatment acts on killing the primary tumour. One of the main downside of 
treatments after the tumour metastasize is an effective delivery of the drugs in 
all sites and chemotherapeutic regiments are often useless at this stage of the 
pathology. Moreover, the identified drugs may have a better effects in 
treatment of particular cancers as based on the tissue specificity of that 
particular cancer, resulting in less toxic side effects for the patients or allowing 
the reduction of concentrations of other drugs used in conjunction with the 










 There are many remaining questions that must be answered regarding 
nuclear size regulation during cancer progression and its potential targeting to 
reduce the metastatic potential of tumours. Deeper investigation of the 
mechanisms by which several different NETs can contribute to maintaining a 
normal nuclear size is crucial to understand the role of the NE both for normal 
functioning and what happens in a complex disease such as cancer. These 
mechanisms can range from potential enzymatic activities of these proteins, 
for which little is known, to complex interactions with the cytoskeleton that can 
be lost if the protein is down regulated in its expression during cancer 
progression. Understanding these mechanisms and interactions can provide 
new insights on new targets for drug development or repurposing. 
 Along with new targets, targeting nuclear size as a macroscopic 
phenotype can be a valuable approach in developing new drugs that can 
reduce the metastatic potential of particularly aggressive tumours. As shown 
with this study, targeting nuclear size as a phenotype can result in a less 
migratory effect on different cancer types and in a type-specific manner and 
can separately reduce tumour growth via selectively triggering apoptosis. 
These identified compounds can be translated in the clinic as additional drugs 
to reduce metastatic spread of the tumour and if proven particularly effective 
in vivo might result in lower dosages and toxicity for the patients. 
 Finally, one of the most important aspects identified in this study is that 
effects on nuclear size are tissue specific and therefore causes of alteration of 
this morphological feature and its regulation should be focused on more tissue 
specific elements such as NETs. Moreover, this tissue specificity is transpose 
also in drug treatments with compounds identified being cell line specific, 
suggesting that drug screening and identification of new drugs should focusing 
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on a selected type of cancer, rather than trying to target multiple diseases at 




6.7 Final remarks 
	
 
The work presented herein and the recent interest in nuclear size 
regulation and factors that can influence it, allow to hypothesise the 
involvement of this phenotypic feature as possible targeting strategy for highly 
aggressive cancer. This study focused on the identification of proteins involved 
in the process of regulate the nuclear size and compounds that can alter or 
restore it, presenting phenotypic screening procedures that can be a used and 
implemented for identification of new targets or compounds. By the 
understanding and further investigation on both mechanism and interaction of 
proteins resident at the NE will open new directions in drug discovery and 
repurposing. In particular, NET50 results as interesting new target influencing 
the nuclear size in prostate cancer due to the ability to alter the nuclear size, 
and could be a new protein to both identify mechanisms of nuclear size 
regulation and as a new drug target. 
Moreover, this study points out a more tissue specific direction where 
compounds and proteins can have completely different, and sometime 
opposite, effects on the phenotype detected, suggesting an alternative aspect 
in which focus future researches. Finally, targeting nuclear size with 
compounds results a tissue specific process, in which drugs have different 
effects depending on the cancer type they are administered, pointing out that 
more focused screen on tissue specificity can improve the successful 
identification of new drugs able to reduce the metastatic potential of highly 
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Compounds screen Script 
 
// Adapted from NucleiCounting and extended to do single cell statistics.  
 
// Input parameters 
 
input(IN_ImageField, 0, "Image Field", "i", "Number of the image field to 
analyze. If set to 0 all image fields of the well are processed.") 
input(nuc_Channel, 1, "Channel number for the nucleus stain") 
input(cyto_Channel, 2, "Channel number for cytoplasm detection") 
input(filename_output,"c:/temp/testdata.txt","Filename for Results","s") 
 




  set(NumberOfChannels=1) // needs to be adapted when 




// Check inputs 
 
if( nuc_Channel>NumberOfChannels or nuc_Channel<0 )  error( "Illegal 
Nuclear Channel selection" )  end() 
	 162	
 






set(ProcessedImageFields = 0) 
set(totalCellNumber = 1) 
 
// LOOP OVER ALL FIELDS (or just the selected one) 
 
FOREACH(StartField .. EndField, "_FieldCounter") 
 
 // Get images of the current image field and select the nucleus image 
(channels are named IM_CH1, IM_CH2, etc.) 
 
 OperaTemplates::AssignPlane() 
 set(IM_nuc = _["IM_CH" & nuc_Channel]) 
 set( IM_cyto=_["IM_CH" & cyto_Channel] ) 
 
 // Don't try to analyse invalid fields 
 if(IM_nuc.max==0) 
  Continue() 
 end() 
 




 // do NUC stuff 
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    rename(objects=nuclei) 
    RemoveBorderObjects() 
    rename(nuclei=objects) 
 
      // get cytoplasm information 
 
    Cytoplasm_Detection_a(IM_cyto,ShowIllustrations=no) // detects cells by 
channel 1 image (cytoplasm is not stained on many channel 2 images) 
    CytoplasmRegion(Stencil="Body",ShowIllustrations=yes, 
WholeCells=wholecells) 
    CalcIntensity(Cytoplasm, image=IM_cyto, objects=wholecells | 
wholecells=objects) 
    CalcIntensity(Centers, image=IM_cyto, objects=wholecells | 
wholecells=objects) 
    CalcArea(CytoplasmRegion, objects=wholecells | wholecells=objects) 
    RingRegion(ShowIllustrations=no, WholeCells = wholecells) 
    CalcIntensity(RingRegion, image=IM_cyto, objects=wholecells | 
wholecells=objects) 
    //imageview(Wholecells.RingRegion, "Ring Region", image=IM_cyto, 
gamma=3) 
    NucleusRegion(VisualImage=IM_cyto, WholeCells = wholecells) 
    CalcIntensity(NucleusRegion,image=IM_cyto, objects=wholecells | 
wholecells=objects) 
 
 // Add nuclei to the all_nuclei list 
 





   // Add cytoplasm  to the all_cytoplasm list 
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 AddObjects(WholeCells, objects=all_cytoplasm, CheckOverlap=no, 
DeleteGeometry=yes) 
    rename(all_cytoplasm=objects) 
                    set(_Wellindex_row = floor(wellindex / 1000000)) 
 
                    set(_Wellindex_column = floor ( (wellindex - 
1000000*_wellindex_row)/1000)) 
 
                    push ( _Wellindex_tochar," ","A","B","C","D","E","F", 
"G","H","I","J","K","L","M","N","O","P") 
     if ((_Wellindex_column > 24) or 
(_Wellindex_row>16))     
 set(Out_Wellidx="R"&_Wellindex_row&" C"&_Wellindex_column) 
     else()     
 set(Out_Wellidx=_Wellindex_tochar[_Wellindex_row]&_Wellindex_col
umn) 
     end() 
printfopen(filename_output &"_"& 
Sourcedata.barcode[0]&".txt",append=TRUE) 












    set(totalCellNumber = totalCellNumber  + Nuclei.index.max) 
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 // Count successfully analysed fields 
set( ProcessedImageFields=ProcessedImageFields+1 ) 
END() 
// Numerical outputs 
output( ProcessedImageFields, "Processed Image fields" ) 
output( all_nuclei.count, "Total number of nuclei" ) 
output( nuclei.area.mean, "area nuclei" ) 
output( nuclei.intensity.mean, "intensity nuclei" ) 
output( WholeCells.CytoplasmRegion_area.mean, "area cytoplasm" ) 
output( WholeCells.RingRegion_intensity.mean, "intensity cytoplasm" ) 
output( WholeCells.Cytoplasm_intensity.mean, "intensity of cyto signal in 
nuclei" ) 
 
NETs screen Script 
 
// Adapted from NucleiCounting and extended to do single cell statistics.  
 
// Input parameters 
 
input(IN_ImageField, 0, "Image Field", "i", "Number of the image field to 
analyze. If set to 0 all image fields of the well are processed.") 
input(nuc_Channel, 1, "Channel number for the nucleus stain") 
input(cyto_Channel, 2, "Channel number for cytoplasm detection") 
input(filename_output,"c:/temp/testdata.txt","Filename for Results","s") 
 




  set(NumberOfChannels=1) // needs to be adapted when 





// Check inputs 
 
if( nuc_Channel>NumberOfChannels or nuc_Channel<0 )  error( "Illegal 
Nuclear Channel selection" )  end() 
 






set(ProcessedImageFields = 0) 
set(totalCellNumber = 1) 
 
// LOOP OVER ALL FIELDS (or just the selected one) 
 
FOREACH(StartField .. EndField, "_FieldCounter") 
 
 // Get images of the current image field and select the nucleus image 
(channels are named IM_CH1, IM_CH2, etc.) 
 
 OperaTemplates::AssignPlane() 
 set(IM_nuc = _["IM_CH" & nuc_Channel]) 












 ////////////////////////////////////////////   COLOR OVERLAY IMAGE    
//////////////////////////////////////////// 
 
    // Create and display a color overlay image of the three channels 
 
    gamma(2.5, image=IM_cyto | Red=image) 
    gamma(2.5, image=IM_nuc | Green=image) 
    gamma(2.5, image=IM_nuc | Blue=image) 
    RgbJoin(Red, Green, Blue, method="fillrangeall" | JoinedImage=image)     
// Acapella 2.0 
    delete(Red, Green, Blue) 
 
    // Do the actual image analysis 
 Nuclei_Detection_Select(IM_nuc) 
 
 // do NUC stuff 
 
    rename(objects=nuclei) 
    RemoveBorderObjects() 
 CalcArea(Border) 
 CalcAttr(Roundness, 3.54491*sqrt(area-
border_area/2.0)/border_area-0.1) // corrected roundness replacing 
CalcAttr( "Roundness" ), see Online Help 
 CalcWidthLength() 
 DefineAttr( WidthToLength, "2*half_width / full_length" ) 
    rename(nuclei=objects) 
 
    // get cytoplasm information 
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    Cytoplasm_Detection_a(IM_cyto) // detects cells by channel 1 image 
(cytoplasm is not stained on many channel 2 images) 
    CytoplasmRegion(Stencil="Body",ShowIllustrations=no, 
WholeCells=wholecells) 
    CalcIntensity(Cytoplasm, image=IM_cyto, objects=wholecells | 
wholecells=objects) 
    CalcIntensity(Centers, image=IM_cyto, objects=wholecells | 
wholecells=objects) 
    CalcArea(CytoplasmRegion, objects=wholecells | wholecells=objects) 
    RingRegion(ShowIllustrations=no, WholeCells = wholecells) 
    CalcIntensity(RingRegion, image=IM_cyto, objects=wholecells | 
wholecells=objects) 
 
    //imageview(Wholecells.RingRegion, "Ring Region", image=IM_cyto, 
gamma=3) 
    NucleusRegion(VisualImage=IM_cyto, WholeCells = wholecells) 
    CalcIntensity(NucleusRegion,image=IM_cyto, objects=wholecells | 
wholecells=objects) 
    CalcAttr("NetExpressed", "RingRegion_intensity - 
NucleusRegion_intensity", objects=wholecells | wholecells=objects) 
 
 // Add nuclei to the all_nuclei list 
 






   // Add cytoplasm  to the all_cytoplasm list 
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 AddObjects(WholeCells, objects=all_cytoplasm, CheckOverlap=no, 
DeleteGeometry=yes) 
    rename(all_cytoplasm=objects) 
                    set(_Wellindex_row = floor(wellindex / 1000000)) 
                    set(_Wellindex_column = floor ( (wellindex - 
1000000*_wellindex_row)/1000)) 
                    push ( _Wellindex_tochar," ","A","B","C","D","E","F", 
"G","H","I","J","K","L","M","N","O","P") 
     if ((_Wellindex_column > 24) or 
(_Wellindex_row>16))     
 set(Out_Wellidx="R"&_Wellindex_row&" C"&_Wellindex_column) 
     else()     
 set(Out_Wellidx=_Wellindex_tochar[_Wellindex_row]&_Wellindex_col
umn) 















    set(totalCellNumber = totalCellNumber  + Nuclei.index.max) 
 
 // Count successfully analysed fields 
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 set( ProcessedImageFields=ProcessedImageFields+1 ) 
END() 
 
// Numerical outputs 
 
output( ProcessedImageFields, "Processed Image fields" ) 
output( all_nuclei.count, "Total number of nuclei" ) 
output( nuclei.area.mean, "area nuclei" ) 
output( nuclei.intensity.mean, "intensity nuclei" ) 
output( WholeCells.CytoplasmRegion_area.mean, "area cytoplasm" ) 
output( WholeCells.RingRegion_intensity.mean, "intensity of net in 
cytoplasm" ) 
output( WholeCells.NucleusRegion_intensity.mean, "intensity of net in nuclei" 
) 
 
List of plasmids used in this study  
 
#Addgene	 Addgene	name	 Log	♯	 Name	 Alias	
		 		 447	 NET26	pmRFP-N2	 		






		 		 485	 mNET20	mRFP	 		
		 		 489	 NET50	pmRFP-N2	 		
61984	 NET31	pEGFP-N2	 490	 NET31	pmRFP-N2	 		
		 		 588	 Emerin	pEGFP-N2	 		
		 		 593	 NET47	pEGFPNN2	 		
61987	 NET51	pEGFP-N2	 594	 NET51	pEGFP-N2	 		
61988	 NET23	pEGFP-N2	 596	 NET23	pEGFP-N2	 		
		 		 597	 NET33	pEGFP-N2	 		
		 		 607	 NET37	GFP	 		
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		 		 609	 NET43	GFP	 		
		 		 610	 NET55	GFP	 		
		 		 637	 Emerin	GFP-C1	 		
		 		 641	 NET97	pmRFP-N2	 		
61995	 LBR	pmRFP-N2	 643	 LBR	pmRFP-N2	 		
		 		 645	 NET37	GFP	 		
		 		 646	 LBR	pEGFP-N2	 		
		 		 663	 STT3A		pmRFP	 NET99	
		 		 700	 NET45	pmRFP-N2	 		
		 		 719	 NKP9	pmRFP-N2	 		
		 		 721	 TAPBPL	pmRFP-N2	 		
		 		 787	 NKP90	RFP	 		
62002	 NKP37	RFP	 788	 NKP37	RFP	 		
		 		 790	 NKP68	RFP	 		
62004	 NKP83	RFP	 791	 NKP83	RFP	 		
62005	 NKP16	RFP	 793	 NKP16	RFP	 		
		 		 794	 NKP40	RFP	 		
		 		 800	 Tmem38A	mRFP-N2	 mNET1	
		 		 802	 Sec61	GFP-C1	 		
62009	 NKP63	RFP	 805	 NKP63	RFP	 		
62010	 SUN2	GFP	 812	 SUN2	GFP	 		
		 		 815	 NET30	pEGFP-N2	 		
62012	 NET59	pEGFP-N2	 816	 NET59	pEGFP-N2	 		
62013	 NET92	RFP	 822	 NET92	RFP	 		
62014	 NET94	RFP	 823	 NET94	RFP	 		
62015	 NET100	RFP	 824	 NET100	RFP	 		
62016	 NET84	RFP	 825	 NET84	RFP	 		
		 		 890	 METTL7A	GFP	 		
62018	 WFS1	pmGFP-N2	 891	 WFS1	pmGFP-N2	 		
62019	 CKAP4	pmRFP	 894	 CKAP4	pmRFP	 mNETY	
		 		 1007	 NKP64	GFP	 		
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		 		 1009	 NKP38	GFP	 		
		 		 1032	 NKP33	GFP	 		
		 		 1034	 NKP91	GFP	 		
		 		 1045	 NET39	GFP-C1	 		
		 		 1051	 STT3A	pEGFP-N2	 NET99	
		 		 1072	 Tmem214	pEGFP-N2	 		
		 		 1074	 Tmem194	pEGFP-N2	 		
		 		 1078	 RHBDD1	pEGFP-N2	 NET82	
62029	 POPDC2	pmRFP-N2	 1085	 POPDC2	pmRFP-N2	 mNET3	
		 		 1087	 POPDC2	pEGFP-N2	 mNET3	
62031	 KLHL31	pgkRFP	 1088	 KLHL31	pgkRFP	 mNET8	
62032	 KHLH31	pEGFP-N2	 1089	 KHLH31	pEGFP-N2	 mNET8	
62033	 Tmem70	pEGFP-N2	 1092	 Tmem70	pEGFP-N2	 		
62034	 NET5s	pEGFP-N2	 1154	 NET5s	pEGFP-N2	
SAMP1,	
Imo1	
62035	 NET5L	pEGFP-N2	 1155	 NET5L	pEGFP-N2	
SAMP1,	
Imo2	
		 		 1159	 Emerin	Active	GFP	 		
		 		 1159	 Emerin	Resting	GFP	 		
62036	 NET77	GFP	 1173	 NET77	GFP	 		
62037	 NKP22	GFP	 1174	 NKP22	GFP	 		
62038	 NKP40	GFP	 1175	 NKP40	GFP	 		
		 		 1176	 NKP66	GFP	 		
		 		 1181	 NET29A.Hs	pEGFP-N2	 		
		 		 1201	 NET4	pEGFP-N2	 		
		 		 1219	 NET39	RFP-C1	 		
		 		 1285	 NET39	GFP-C1	 		
		 		 1299	 NLS	pEGFP-N3	 		
62044	 		 1317	 LAP2	Full	I	pAcGFP-N1	 		
		 		 1326	 NET29A.Mm	pEGFP-N2	 Tmem120a	
		 		 1327	 NET29b.Mm	pEGFP-N2	 		
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		 		 1348	 Tmem214	pmRFP-N2	 		
		 		 1389	 Tmem194	pmRFP-N2	 		
		 		 1390	 RHBDD1	pmRFP-N2	 NET82	
		 		 1401	 Tmem38A	pEGFP-N2	 mNET1	




		 		 1764	 NET51	pEGFP-C3	 		
		 		 1765	 TAPBPL	pEGFP-C3	 		
62056	 		 1766	 LBR	GFP-C3	 		
		 		 1768	 NET34	GFP	 		
		 		 1769	 NET51	pEGFP-N2	 		
		 		 1771	 NET99	GFP	 		
		 		 1772	 NKP9	GFP	 		
		 		 1774	 LAP2b	GFP	 		
 
 
 
 
	
